- 1 Analysis of SARS-Covering 211 and Mathematic monoclonal and anti-bodies that and antibodies that $\frac{1}{2}$ emerge after treatment. 2 emerge after treatment.
3
4 Daniele Focosi^{1,#}
-
-
- 4
5 5 Scott McConnell²
6 David J. Sullivan²
- 6 David J. Sullivan²
7 Arturo Casadeval
- 7 Arturo Casadevall²
8
-
- 7 Arturo Casadevall⁴
8 ^{— 1}North-Western Tu 9
0
1 t,
- 9 ² Department of Molecular Microbiology and Immunology, Johns Ho
1 Health, Baltimore, MD 21205, USA.
2 2
- 11 Health, Baltimore, MD 21205, USA.
12
13 Teorresponding author: daniele foces @gmail.com
-
- 12
13 ***corresponding author: <u>daniele.focc</u> 12
13
14 #
-
- 15 Word counts: abstract: 235; body 1941.

 $\frac{16}{17}$ Examination of the strovens; santifieds: 16 Keywords: COVID-19; SARS-CoV-2; monoclonal antibodies; sotrovimab; casirivimab; imdevimab;
17 tixagevimab; cilgavimab.
18 Author contributions: D.F. performed literature search a

- 16 Keywords: COVID-19; SARS-COV-2; monoclonal antibodies; sotrovimab; casirivimab; imdevimab;
18 Author contributions: D.F. performed literature search and wrote the first draft. A.C. revised the
19 manuscript. D.J.S. revi 18 Author contributions: D
19 manuscript. D.J.S. revised
- manuscript. D.J.S. revised the manuscript and curated Table 3. S.M. designed Figure 2.
20 **Conflict of interest statement**: We declare we have no COI related to this manuscript.
21 **Funding**: none. Conflict of interest statement: We declare we have no COI related to this manuscript. 20 Conflict of interest statement: We declare we have no COI related to this manuscript.
21 Funding: none.
22
-
-

21 Funding: none.
22
23 Abstract

23
24
25 23 Abstract
24 The mut:
25 authorize
26 authorize 25 authorized anti-Spike monoclonal antibodies (mAbs). Nevertheless, in case more antiviral mAbs will be authorized in the future, it is relevant to understand how frequently treatment-emergent resistance has emerged so fa 26 authorized in the future, it is relevant to understand how frequently treatment-emergent resistance has
27 emerged so far, under different combinations and in different patient subgroups. We report the results
28 of a s emerged so far, under different combinations and in different patient subgroups. We report the results
28 of a systematic review of the medical literature for case reports and case series for treatment-emergent
29 immune e 28 of a systematic review of the medical literature for case reports and case series for treatment-emergent
29 immune escape, which is defined as emergence of a resistance-driving mutation in at least 20% of
30 sequences 29 immune escape, which is defined as emergence of a resistance-driving mutation in at least 20% of
30 sequences in a given host at a given timepoint. We identified 31 publications detailing 201 cases that
31 included diff 30 sequences in a given host at a given timepoint. We identified 31 publications detailing 201 cases that
31 included different variants of concern (VOC) and found that the incidence of treatment emergent-
32 immunocompro 31 included different variants of concern (VOC) and found that the incidence of treatment emergent-
32 resistance ranged from 10% to 50%. Most of the treatment-emergent resistance events occurred in
33 immunocompromised pa 33 immunocompromised patients. Interestingly, resistance also emerged against cocktails of two mAbs,
34 albeit at lower frequencies. The heterogenous therapeutic management of those cases doesn't allow
1 34 albeit at lower frequencies. The heterogenous therapeutic management of those cases doesn't allow
1

-
- 35 inferences about the clinical outcome in patients with treatment-emergent resistance. Furthermore, we
36 noted a temporal correlation between the introduction of mAb therapies and a subsequent increase in
37 SARS-CoV-2
-
-
- 37 SARS-CoV-2 sequences across the globe carrying mutations conferring resistance to that mAb, raising
38 concern as to whether these had originated in mAb-treated individuals. Our findings confirm that
39 treatment-emerge 38 concern as to whether these had originated in mAb-treated individuals. Our findings confirm that
39 treatment-emergent immune escape to anti-Spike mAbs represents a frequent and concerning
40 phenomenon and suggests tha 39 treatment-emergent immune escape to anti-Spike mAbs represents a frequent and concerning
40 phenomenon and suggests that these are associated with mAb use in immunosuppressed hosts.
- phenomenon and suggests that these are associated with mAb use in immunosuppressed hosts. 40 phenomenon and suggests that these are associated with mAb use in immunosuppressed hosts.

41 Introduction
42 Passive antib
44 antibodies (m 142 Passive anti-exposure and pre-experience proping and treatments are main according
44 antibodies (mAb) have been the treatment of choice since early 2021. The biologicals were safe, well
45 tolerated and efficient at p antibodies (mAb) have been the treatment of choice since early 2021. The biologicals were safe, well
45 tolerated and efficient at preventing disease and reducing the likelihood of progression to severe
46 disease. Unfort tolerated and efficient at preventing disease and reducing the likelihood of progression to severe
46 disease. Unfortunately, the advent of the Omicron VOC progressively defeated the emergency use
47 authorized mAbs, leavi disease. Unfortunately, the advent of the Omicron VOC progressively defeated the emergency use
authorized mAbs, leaving all revoked by the US Food and Drug Administration at the time of writing. The
48 COVID-19 pandemic ha disease. Unfortunately, the advent of the Omicron VOC progressively defeated the emergency use
authorized mAbs, leaving all revoked by the US Food and Drug Administration at the time of writing. The
COVID-19 pandemic has r 48 COVID-19 pandemic has represented the first instance of large-scale deployments of passive
49 immunotherapies against an infectious agent, and with persistence at epidemic levels and fluctuations
50 in the dominant vari 49 immunotherapies against an infectious agent, and with persistence at epidemic levels and fluctuations
50 in the dominant variants, it is possible that this scenario will persist for more years. This in turn provides
51 49 in the dominant variants, it is possible that this scenario will persist for more years. This in turn provides
49 in a unique opportunity to study the phenomenon of emerging resistance to antibody-based therapeutics.
49 a unique opportunity to study the phenomenon of emerging resistance to antibody-based therapeutics.
52 The emergence of mAb-resistant variants after individualized therapy has potential public health
53 implications if the 52 The emergence of mAb-resistant variants after individualized therapy has potential public health
53 implications if these viruses re-enter the general population and are able to evade vaccine or prior
55 infection immun 53 implications if these viruses re-enter the general population and are able to evade vaccine or prior
54 infection immunity by virtue of their mutations (Casadevall and Focosi, 2023) Here we analyzed mAbs
55 resistance p Examples in these viruses results in general population and are able to evade vacuum in prior interferent in the
54 infection immunity by virtue of their mutations (Casadevall and Focosi, 2023) Here we analyzed mAbs
55 res 54 infection immunity by virtue of their mutations (Casadevall and Focosi, 2023)Here we analyzed mAbs
55 resistance patterns following therapy principally in immunosuppressed but sometimes in
56 immunocompetent COVID-19 pa 56 immunocompetent COVID-19 patients.
57 Materials and methods
58 Ligating haseling resistance to anti-Saike manaclanal antibodies

57 Immunocompetent COVID-19 patients.
57 **Materials and methods**
58 Inferring baseline resistance to anti-Spik

57 Materials and methods
58 *Inferring baseline resista*
59 The Stanford University Inferring baseline resistance to anti-Spike monoclonal antibodies.
59 The Stanford University Coronavirus Antiviral & Resistance Database is a comprehensively curated
60 collection of published data on the susceptibility o 50 collection of published data on the susceptibility of SARS-CoV-2 variants to anti-Spike mAbs and the
51 plasma from previously infected and/or vaccinated persons. It also records the Spike protein mutations
52 that are 61 plasma from previously infected and/or vaccinated persons. It also records the Spike protein mutations
62 that are selected by mAbs and that emerge in persons experiencing prolonged infection (Tzou et al.,
63 2020). It that are selected by mAbs and that emerge in persons experiencing prolonged infection (Tzou et al.,
63 2020). It is publicly accessible at https://covdb.stanford.edu/. For each authorized anti-Spike mAb, we
64 manually sca 63 2020). It is publicly accessible at $\frac{https://covdb.stanford.edu/}{https://covdb.stanford.edu/}$. For each authorized anti-Spike mAb, we
64 manually scanned mutations associated with >5-fold median reduction in neutralizing antibody (nAb)
65 titers from manually scanned mutations associated with >5-fold median reduction in neutralizing antibody (nAb)
65 titers from primary research listed in search results provided at https://covdb.stanford.edu/search-
66 drdb/?form_only. titers from primary research listed in search results provided at https://covdb.stanford.edu/search-
66 drdb/?form only. The cutoff was arbitrarily chosen by the authors based on former literature suggesting
67 loss of the Formulation of the cutofficacy.
Expeditions of the cutoff was arbitrarily chosen by the control of the cutoff was arbitrarily chosen by the authors based on ϵ on ϵ and ϵ on ϵ and ϵ on ϵ and ϵ on ϵ a

65 titers from primary research listed in search results provided at https://covdb.stanford.edu/search-

1058 of therapeutic efficacy.
1586 Literature search
1696 On February 1 2023, we searched PubMed, bioRxiv and medRxiv repositories for literature published
1696 Since January 1 2020 to February 1 2023 using English languag 69 Different Search

69 On February 1 20

70 Since January 1 2

71 "("sotrovimab" O 69 Since January 1 2020 to February 1 2023 using English language as a restriction. We used the query

10 Since January 1 2020 to February 1 2023 using English language as a restriction. We used the query

12 OR "imdevimab The "the Sotrovimal" CR" ("sotrovimal" CR" tixagevimab" OR "cilgavimab" OR "bamlanivimab" OR "etesevimab" OR "casirivimab"
12 OR "imdevimab" OR "bebtelovimab" OR "regdanvimab") AND ("resistance" OR "escape" OR "evasion"
13 OR "imdevimab" OR "bebtelovimab" OR "regdanvimab") AND ("resistance" OR "escape" OR "evasion"
73 OR "evolution")". The PRISMA flowchart is reported in Figure 1. We excluded all primary research on
75 about sample size unde 22 OR "evolution")". The PRISMA flowchart is reported in Figure 1. We excluded all primary research on

baseline (as opposed to treatment-emergent) resistance and all secondary research. We collected data

about sample siz baseline (as opposed to treatment-emergent) resistance and all secondary research. We collected data
75 about sample size, underlying immunosuppression and incidence of *de novo* mutations at Spike residues
76 associated w The Saseline (as opposed to treatment-emergent) resistance and all secondary research. We collected data

25 about sample size, underlying immunosuppression and incidence of *de novo* mutations at Spike residues

27 associ 75 about sample size, underlying immunosuppression and incidence or de novo mutations at Spike residues
76 associated with mAb escape.
79 Determining the temporal relationship between mAb authorization and alobal prevalenc

Determining the temporal relationship between mAb authorization and global prevalence 78 78 Determining the temporal relationship between mAb authorization and global prevalence

79 On February 1 2023 we searched CoV-Spectrum.org (Chen et al., 2021a) for worldwide prevalence of SARS-CoV-2 sublineages carrying either at least one mutation conferring resistance to a given mAb or just the major resist

81 just the major resistance associated mutations (i.e., Q493X for bamlanivimab and etesevimab, R346X for
82 cilgavimab, K444X for bebtelovimab).
83 82 cilgavimab, K444X for bebtelovimab).
83
84 Manning treatment emergent mutations to the structures of Snike: mAb complexes

-
-

84 Mapping treatment emergent mutations to the structures of Spike: mAb complexes

85
86

85 All three-dimensional molecular representations were generated with PyMOL
86 Deposited structures of therapeutic mAbs in complex with the Spike protein we
87 Protein Database (PDB) under the accession numbers 7KMG (baml Representational molecular representation in the generator representations of the Deposited structures of therapeutic mAbs in complex with the Spike protein were obtained from the
87 Protein Database (PDB) under the access

87 Protein Database (PDB) under the accession numbers 7KMG (bamlanivimab), 7C01 (etesevimab), 6XDG
88 (casirivimab/imdevimab), 7L7E (cilgavimab), 7L7D (tixagevimab) and 6WPS (sotrovimab).
89 88 (casirivimab/imdevimab), 7L7E (cilgavimab), 7L7D (tixagevimab) and 6WPS (sotrovimab).
89
90 Results

89 (casirivimab), 7L7E (cigavimab), 7L7E (cingavimab), 7L7E (circagevimab) and 6WPS (southwab).
89
90 Results

91
92

91 The indi
92 A review
93 with m/ 92 A review of 31 publications reporting mAb resistance yielded a list of Spike protein mutations associated
93 with mAb resistance (Table 2). From these publications we identified 201 out of 1060 patients who
95 experienc

with mAb resistance (Table 2). From these publications we identified 201 out of 1060 patients who
94 experienced emergence of resistant SARS-CoV-2 after treatment with one of the anti-Spike mAb. As
95 expected from real-wo

-
- with mAb resistance (Table 2). From these publications we identified 201 out of 1060 patients who
experienced emergence of resistant SARS-CoV-2 after treatment with one of the anti-Spike mAb. As
expected from real-world in expected from real-world indications and usage, the majority of these patients were
96 immunocompromised, but immunocompetent patients were also noted (Sabin et al., 2022).
97 26 publications reported incidence rates while 96 immunocompromised, but immunocompetent patients were also noted (Sabin et al., 2022).
97 26 publications reported incidence rates while investigating a cohort: among them the incidences varied
98 between 0% to 100% with 96 196 26 publications reported incidence rates while investigating a cohort: among them the incident between 0% to 100% with overall 195/1079 or 18.1%. In particular bamlanivimab (n=5) rand to 83%, sotrovimab (n=10) from
-
-

between 0% to 100% with overall 195/1079 or 18.1%. In particular bamlanivimab (n=5) ranged from 11
199 to 83%, sotrovimab (n=10) from 16 to 100%, while dual mAbs (n=10) ranged from 0% to 50%.
100 The majority of resistant 1988 to 83%, sotrovimab (n=10) from 16 to 100%, while dual mAbs (n=10) ranged from 0% to 50%.

The majority of resistant cases from cohorts were reported after mAb monotherapies bamlanivimab

(23/160-14%) or sotrovimab (13 99 The majority of resistant cases from cohorts were reported after mAb monotherapies bar
99 (23/160-14%) or sotrovimab (131/427-31%) as opposed to mAb cocktails bamlanivimab+ (n=10) ranged from 0.00
92 (15/270-6%) or casi

101 (23/160-14%) or sotrovimab (131/427-31%) as opposed to mAb cocktails bamlanivimab+ etesevimab
102 (15/270-6%) or casirivimab+ imdevimab (16/185-9%) (Table 3). The cilgavimab+ tixagevimab essentially
103 had a single ac 101 (23/160-14%) or sotrovimab (131/427-31%) as opposed to mAb cocktails bamlanivimab+ etesevimab

102 (15/270-6%) or casirivimab+ imdevimab (16/185-9%) (Table 3). The cilgavimab+ tixagevimab essentially

103 had a single

-
- had a single active mAb during most of its deployment and the rate in the series cohorts was similar to

104 single monoclonals (10/37-27%).

105 Studies with a specific mAb or mAb cocktail largely reported the same set of 104 single monoclonals (10/37-27%).
105 Studies with a specific mAb or mAb cocktail largely reported the same set of emerging Spike mutations
106 (e.g., Q493X and E484X for bamlanivimab, P337X and E340X for sotrovimab). 105 Studies with a specific mAb or m
106 (e.g., Q493X and E484X for bamla
107 By querying the Spike protein

106 (e.g., Q493X and E484X for bamlanivimab, P337X and E340X for sotrovimab).
107 By querying the Spike protein sequence database for the major mutations associated with mAb-
108 resistance we noted that these mutations em 107 By querying the Spike protein sequence database for the major mutations resistance we noted that these mutations emerged in the general population of the major sotrovimable after marketing authorization of the mAbs to 111 bamlanivimab and etesevimab, in addition to casirivimab and regdanvimab) in Omicron BA.1 shortly resistance we noted that these mutations emerged in the general population across the globe shortly
109 after marketing authorization of the mAbs to whom they confer resistance (Figure 3). The most striking
110 examples ar examples are the emergence of S:Q493R (the single mutation conferring resistance to both
111 bamlanivimab and etesevimab, in addition to casirivimab and regdanvimab) in Omicron BA.1 shortly
112 after the massive deployment 111 bamlanivimab and etesevimab, in addition to casirivimab and regdanvimab) in Omicron BA.1 shortly
112 after the massive deployment of bamlanivimab/etesevimab cocktail, and the emergence of S:R346X in
113 many converging after the massive deployment of bamlanivimab/etesevimab cocktail, and the emergence of S:R346X in
113 many converging Omicron sublineages shortly after the massive deployment of cilgavimab for post-
114 exposure prophylaxi 114 exposure prophylaxis in immunosuppressed patients. There was a single case report of bebtelovimab 115 resistance (S:V445A post treatment in an immunocompromised patient with the B.1.23 lineage. 115 essistance (S:V445A post treatment in an immunocompromised patient with the B.1.23 lineage.
116 116 resistance (S:V445A post transmised patient patient with the B.1.23 lineage.
116

 116

117 Discussion
118 The emerge
119 The discrep
120 detected in The discrepancy between the diversity of mutations reported *in vitro* (Table 1) and the few ones
120 detected *in vivo* (Table 2) can be explained by various factors. First, not all mutants selected *in vitro* are
121 fit 119 The discrepancy between the diversity of mutations reported in vitro (rable 1) and the rew ones
120 detected in vivo (Table 2) can be explained by various factors. First, not all mutants selected in vitro are
121 fit e 120 detected *in vivo* (Table 2) can be explained by various factors. First, not all mutants selected *in vitro* are
121 fit enough to compete within the intrahost quasispecies swarm. Fitness would include the ability to b 122 to its cellular receptor as well capacity for virion stability and assembly. The large number of mutations
123 shown to confer resistance in vitro that are not reflected in the clinical data could be rationalized by th to its cellular receptor as well capacity for virion stability and assembly. The large number of mutations
123 shown to confer resistance *in vitro* that are not reflected in the clinical data could be rationalized by the
 126 Second, in many cases some mutations were already occurring at baseline (e.g., F486X in patients 127 treated with tixagevimab). Third, among the residues wild-type at baseline, the mutations associated Fact that a reduction in nAb titers measured in vitro reflects a defect in antibody binding to spike
125 variants but does not report on the relative efficacy of ACE2 binding compared to the ancestral Spike.
127 treated wi Second, in many cases some mutations were already occurring at baseline (e.g., F486X in patients
127 treated with tixagevimab). Third, among the residues wild-type at baseline, the mutations associated
128 be a notoriety h 127 treated with tixagevimab). Third, among the residues wild-type at baseline, the mutations associated
128 with the highest fold-reduction in neutralization have been more commonly reported: while this could
129 be a not with the highest fold-reduction in neutralization have been more commonly reported: while this could
129 be a notoriety bias by the investigators (placing more attention to the mutations which have been
130 previously repo the a notoriety bias by the investigators (placing more attention to the mutations which have been
130 previously reported), it is likely that as soon as one of the highly resistant mutations emerges,
131 emergence of addi 130 be a noticity and by the investigators (placing more attention to the mutations investigators)
131 emergence of additional mutations do not provide any further fitness advantage.
132 No cases of treatment-emergent resi previously reported), it is likely that as soon as one of the highly resistant mutations emerges,
131 emergence of additional mutations do not provide any further fitness advantage.
132 No cases of treatment-emergent resis

132 No cases of treatment-emergent resistance have been reported in the m
133 ergdanvimab: this is likely due to usage much limited in time and location
134 Regdanvimab is not effective against Omicron lineages, limiting i 133 regdanvimab: this is likely due to usage much limited in time and locations across the globe.
134 Regdanvimab is not effective against Omicron lineages, limiting its use toa few weeks in the end 2021.
135 Most anti-Spi

134 Regdanvimab: this is likely due to usage much interest in time can receive the globe.
135 Rost anti-Spike mAbs authorized thus far were not formally investigated in randomized controlled
136 trials (RCT) involving immu Regdanvimab is not effective against Omicron lineages, limiting its use toa few weeks in the end 2021.

135 Most anti-Spike mAbs authorized thus far were not formally investigated in randomized controlled

136 trials (RCT) 136 trials (RCT) involving immunocompromised patients prior to deployment (Focosi et al., 2022a).
137 Immunocompromised patients are at increased risk for anti-Spike mAb treatment-emergent resistance
138 for multiple risk Immunocompromised patients are at increased risk for anti-Spike mAb treatment-emergent resistance
138 for multiple risk factors: higher basal viral load, higher likelihood of viral persistence because of
139 inadequate imm 138 for multiple risk factors: higher basal viral load, higher likelihood of viral persistence because of
139 inadequate immune response, and contraindications to other directly-acting antivirals (Casadevall and
140 Focosi 138 for multiple risk factors: higher basal viral load, higher likelihood of viral persistence because of inadequate immune response, and contraindications to other directly-acting antivirals (Casadevall and Focosi, 2023). Focosi, 2023). Resistance monitoring is not routinely performed after outpatient mAb treatment, and

143 Despite FDA deauthorization, many US physicians continued prescription of deauthorized anti-Spike 144 mAbs(Anderson et al., 2022), mostly based on personal beliefs in discrepancies between in vitro and in 142 Species swarm (Vellas et al., 2022), mostly
143 Despite FDA deauthorization, many
145 *vivo* activities. The latter phenomer mands and the settlement of the settlement of the settlement of the settlement in the settlement of the mand in
145 Device and the latter phenomenon has been much amplified across Europe (Focosi and Tuccori,
146 2022), whe 144 mAbs(Anderson et al., 2022), mostly based on personal beliefs in discrepancies between in vitro and in
145 vivo activities. The latter phenomenon has been much amplified across Europe (Focosi and Tuccori,
146 2022), wh 145 *Vivo activities.* The latter phenomenon has been mach amplified across Europe (Focosi and Tuccori,
146 2022), where EMA has never withdrew a single authorized mAb to date, and only sporadically issued
148 literature i 147 alerts about possible basal resistance. In addition, a plethora of uncontrolled or poorly controlled
148 literature is advocating continued efficacy of anti-Spike mAbs based on marginal gains in surrogate
149 endpoints Iterature is advocating continued efficacy of anti-Spike mAbs based on marginal gains in surrogate

149 endpoints in non-RCTs (Harman et al., 2022) or no change in hospitalization rates of outpatients (Patel

150 et al., 2 149 endpoints in non-RCTs (Harman et al., 2022) or no change in hospitalization rates of outpatients (Patel
150 et al., 2023). While binding affinity seems a robust surrogate endpoint, advocates of residual *in vivo*
151 a 159 et al., 2023). While binding affinity seems a robust surrogate endpoint, advocates of residual in vivo
151 activity argue that the concentrations achieved by mAbs in vivo can overcome several degrees of
152 baseline re 150 et al., 2023). While binding affilmity seems a robust surrogate enapoint, advocates of residual *in vivo*
151 activity argue that the concentrations achieved by mAbs *in vivo* can overcome several degrees of
153 2022a baseline resistance to neutralization or that alternative effector function still persists (Stadler et al., 2022a; Stadler et al., 2022b; Wu et al., 2022). Both arguments do not seem robust: with IC_{50} above 1,000 (Cao 2022a; Stadler et al., 2022b; Wu et al., 2022). Both arguments do not seem robust: with C_{50} above 1,000
154 (Cao et al., 2022) antigen binding by the mAb is compromised, and effector functions other than
155 neutraliz 154 (Cao et al., 2022) antigen binding by the mAb is compromised, and effector functions other than
155 neutralization invariably require binding to the virus to activate Fc-receptors. Under the current variant
156 soup (F neutralization invariably require binding to the virus to activate Fc-receptors. Under the current variant
156 soup (Focosi et al., 2023), the incompatible turnaround time of viral sequencing and therapeutics
157 delivery, 156 soup (Focosi et al., 2023), the incompatible turnaround time of viral sequencing and therapeutics
157 delivery, tools to predict basal efficacy of anti-Spike mAbs based on regional genomic surveillance have
158 been de 156 soup (Focosi et al., 2023), the incompatible turnaround time of viral sequencing and therapeutics
157 delivery, tools to predict basal efficacy of anti-Spike mAbs based on regional genomic surveillance have
158 been de 158 been developed (Focosi, 2023).
158 been developed (Focosi, 2023). 158 been developed (Focosi, 2023).

Of interest, several cases of mAb-treatment-emergent immune escape were rescued with COVID-19
160 convalescent plasma (Halfmann et al., 2022; Pommeret et al., 2021), which, in contrast to mAbs, is
161 polyclonal and thus m

163 acid substitution in the epitope, establishing the high vulnerability of monotherapy for selecting 162 University of the that in many patients the emergence of mAb resist.
163 acid substitution in the epitope, establishing the high vural 164 resistant variants. Emergence of resistance requires selection. acid substitution in the epitope, establishing the high vulnerability of monotherapy for selecting
164 Fesistant variants. Emergence of resistance requires selection of mutant viruses that are fit for
165 Fesiculary patien 164 resistant variants. Emergence of resistance requires selection of mutant viruses that are fit for
165 replication and that could explain the repeated independent isolations of variants with mutations at
166 specific re replication and that could explain the repeated independent isolations of variants with mutations at
166 specific residues, such as in position 484 with bamlanivimab monotherapy. For some mAbs, the
167 senerated footprint 166 specific residues, such as in position 484 with bamlanivimab monotherapy. For some mAbs, the generated footprint is so unique (e.g. S:340X after sotrovimab) that baseline sequencing is not needed to confirm treatment e 166 specific residues, such as in position 484 with bamlanivimab monotherapy. For some mAbs, the generated footprint is so unique (e.g. S:340X after sotrovimab) that baseline sequencing is not needed to confirm treatment e 168 to confirm treatment emergence (S:340X being exceedingly rare in GISAID). The transmissibility of such
169 mAb treatment-generated lineages remains a major concern, and it has been formally demonstrated in
170 at least mAb treatment-generated lineages remains a major concern, and it has been formally demonstrated in
170 at least one study (Sabin et al., 2022). Clinical reports of treatment-emergent resistance in response to
171 the rapeu at least one study (Sabin et al., 2022). Clinical reports of treatment-emergent resistance in response to
171 therapeutic mAbs reviewed here encompass nearly every epitope of the receptor binding domain (RBD),
172 includin therapeutic mAbs reviewed here encompass nearly every epitope of the receptor binding domain (RBD),
172 including all 3 receptor binding motif epitopes and the cross reactive S309 site (Figure 2F). Despite
173 partial or c 172 including all 3 receptor binding motif epitopes and the cross reactive S309 site (Figure 2F). Despite
173 partial or complete overlap of antibody epitope on RBD with the ACE2 interface, these positions
174 demonstrate partial or complete overlap of antibody epitope on RBD with the ACE2 interface, these positions
174 demonstrate remarkable mutability while maintaining receptor affinity.
175 Since therapeutic mAbs ultimately trace their a

demonstrate remarkable mutability while maintaining receptor affinity.
175 Since therapeutic mAbs ultimately trace their ancestry to immune B cells in humans, the emergence of
176 MAb resistance mutations poses the theoret 175 Since therapeutic mAbs ultimately trace their ancestry to immune B ce
176 mAb resistance mutations poses the theoretical concern that once the
177 individuals the mAb-resistant variants can spread to immunocompete mab resistance mutations poses the theoretical concern that once these occur in immunosuppressed

175 Individuals the mAb-resistant variants can spread to immunocompetent populations, bypass existing

178 Inmunity, and cre individuals the mAb-resistant variants can spread to immunocompetent populations, bypass existing
178 immunity, and create new waves of infection (Casadevall and Focosi, 2023). Consistent with this concern
179 in the SARSimmunity, and create new waves of infection (Casadevall and Focosi, 2023). Consistent with this concern
179 we found a temporal association between the introduction of the mAb and an increase in frequency in
180 the SARS-C we found a temporal association between the introduction of the mAb and an increase in frequency in
180 the SARS-CoV-2 Spike protein sequence database. Such temporal association could be explained by a
181 senter whereby t the SARS-CoV-2 Spike protein sequence database. Such temporal association could be explained by a
181 scenario whereby the emergence of these variants in immunosuppressed hosts was followed by their
182 spread among the ge 181 scenario whereby the emergence of these variants in immunosuppressed hosts was followed by their
182 spread among the general population. Such mutations would have created antigenically distinct viruses
183 that could 182 spread among the general population. Such mutations would have created antigenically distinct viruses
183 that could have an advantage in bypassing established immunity in the general population from
184 vaccination an that could have an advantage in bypassing established immunity in the general population from
184 vaccination and prior infection as these occur in a critical neutralizing epitope. We caution that
185 association does not 184 vaccination and prior infection as these occur in a critical neutralizing epitope. We caution that
185 association does not imply causation and that other interpretations are possible. For example, immunity
187 the pos association does not imply causation and that other interpretations are possible. For example, immunity
186 to previous infection waves could be another possible driver for selection of novel Spike variants, and
187 the po 186 to previous infection waves could be another possible driver for selection of novel Spike variants, and
187 the possibility of viral transitioning through animal reservoirs remains as possibility since Q493R is a
189 t 187 the possibility of viral transitioning through animal reservoirs remains as possibility since Q493R is a
188 mouse-adapting mutation, which in turn suggests the possibility of reverse zoonosis. Nevertheless, the
190 mu mouse-adapting mutation, which in turn suggests the possibility of reverse zoonosis. Nevertheless, the
189 the temporal association between mAb introduction in clinical practice and increased frequency of
191 in immunocomp 189 temporal association between mAb introduction in clinical practice and increased frequency of
190 mutations conferring resistance to that mAb is concerning and suggest that future use of mAb therapies
191 in immunocomp mutations conferring resistance to that mAb is concerning and suggest that future use of mAb therapies
191 in immunocompromised populations should consider the use of cocktails and/or combination therapy
192 in the small m 190 mutations conferring resistance to that mAb is concerning and suggest that future use of mAb therapies
191 in immunocompromised populations should consider the use of cocktails and/or combination therapy
192 with small 192 in with small molecule antivirals. Cocktails-of-three or more anti-Spike mAbs with non-overlapping
193 in epitopes could minimize the chances for immune escape.
194 192 with small molecule antibiate of the collection of the competition of plane made in the competition of the
193 epitopes could minimize the chances for immune escape.
194 194
 195

-
- 195

196
197 196 Figure 1. PRISMA flowchart for study selection.

198 Figure 2. Resistance mutations on the Spike receptor binding domain (RBD) reported after treatment
199 with authorized anti-Spike mAbs. A-D) The complex structures of RBD and corresponding therapeutic
100 mAbs are repr man authorized anti-spike matrix by the complete content and corresponded black, the receptor binding

201 motif (residues 438-507) is colored dark gray, and corresponding escape mutations are highlighted in

202 yellow. I 201 motif (residues 438-507) is colored dark gray, and corresponding escape mutations are highlighted in
202 yellow. In the middle panel, the entire RBD-mAb complex is depicted, and expanded and rotated views
203 of each i 202 yellow. In the middle panel, the entire RBD-mAb complex is depicted, and expanded and rotated views
203 of each interface are presented in boxes on each side of the main complex. The interacting mAb is
204 partially t 203 of each interface are presented in boxes on each side of the main complex. The interacting mAb is
204 partially transparent to enable visualization of the full RBD paratope and reported resistance mutations
205 are lab partially transparent to enable visualization of the full RBD paratope and reported resistance mutations
205 are labeled. A) The structural complex of the bamlanivimab/etesevimab mAb cocktail with RBD is
206 depicted. Baml 205 are labeled. A) The structural complex of the bamlanivimab/etesevimab mAb cocktail with RBD is
206 depicted. Bamlanivimab and etesevimab (PDBID 7KMG, 7C01) are colored blue and red, respectively. B)
207 The structural depicted. Bamlanivimab and etesevimab (PDBID 7KMG, 7C01) are colored blue and red, respectively. B)
207 The structural complex of the casirivimab/imdevimab mAb cocktail (REGN-CoV) with RBD is depicted.
208 Casirivimab and 207 The structural complex of the casirivimab/imdevimab mAb cocktail (REGN-CoV) with RBD is depicted.
208 Casirivimab and imdevimab (PDBID 6XDG) are colored salmon and dark green, respectively. C) The
209 structural comple 208 Casirivimab and imdevimab (PDBID 6XDG) are colored salmon and dark green, respectively. C) The
209 structural complex of the cilgavimab/tixagevimab mAb cocktail with RBD is depicted. Cilgavimab and
210 tixagevimab (PDB 209 structural complex of the cilgavimab/tixagevimab mAb cocktail with RBD is depicted. Cilgavimab and
210 tixagevimab (PDBID 7L7E, 7L7D) are colored purple and cyan, respectively. D) The structural complex of
211 the sotr 209 structural complex of the cilgavimab/tixagevimab mAb cocktail with RBD is depicted. Cilgavimab and
210 tixagevimab (PDBID 7L7E, 7L7D) are colored purple and cyan, respectively. D) The structural complex of
211 the sotr 211 the sotrovimab mAb monotherapy with RBD is depicted. Sotrovimab (PDBID 6WPS) is colored light green. E) A summary of the reported treatment-emergent resistance mutations on RBD across all approved anti-Spike therapeuti 212 green. E) A summary of the reported treatment-emergent resistance mutations on RBD across all
213 approved anti-Spike therapeutic mAbs are highlighted on the structure of RBD, shown with the front
214 face, back face approved anti-Spike therapeutic mAbs are highlighted on the structure of RBD, shown with the front
214 face, back face and top RBM view. Escape mutations in the RBM are highlighted in blue, non-RBM
215 mutations are colore 214 face, back face and top RBM view. Escape mutations in the RBM are highlighted in blue, non-RBM mutations are colored red. F) The complexes of the each of the mAbs in complex with RBD are depicted, colored as in panels mutations are colored red. F) The complexes of the each of the mAbs in complex with RBD are depicted,
216 colored as in panels A-D, to illustrate the relative binding angles and epitopes of each mAb.
217 215 mutations are colored red. F) The complexes of the each of the mAbs in complex with RBD
216 colored as in panels A-D, to illustrate the relative binding angles and epitopes of each mAb.
217

218 Figure 3. Timeline of anti-Spike mAb authorizations and emergence of key Spike mutations associated 219 with mAb resistance. Figure generated using Cov-Spectrum.org (Chen et al., 2021a) 218 with mAb resistance. Figure generated using Cov-Spectrum.org (Chen et al., 2021a)

219 with mAb resistance. Figure generated using Cov-Spectrum.org (Chen et al., 2021a)

Table 1. Spike mutations associated with mAb resistance in *in vitro* studies. Bold characters show the ones that have been detected as emerged *in vivo* after treatment with the specific mAb. In cases where the exact amino acid change has not been studied in vitro, only the residue is highlighted. Number within parentheses represent the median fold-reduction in neutralizing antibody titers.

References

ETF warns that monoclonal antibodies may not be effective against emerging strains of SARS-CoV-2.
Accessed online at <u>https://www.ema.europa.eu/en/news/etf-warns-monoclonal-antibodies-may-not-
be-effective-against-emerging</u>

Fact sheet for healthcare providers: emergency use authorization for bebtelovimab. Accessed online a https://www.fda.gov/media/156152/download on February 21, 2022. at <u>https://www.fda.gov/media/149534/download</u> on February 22, 2023.
Fact sheet for healthcare providers: emergency use authorization for bebtelovimab. Accessed online at
<u>https://www.fda.gov/media/156152/download</u> on Febr

at sheet for healthcare providers: emergency use authorization for beb
https://www.fda.gov/media/156152/download on February 21, 2022.
FDA authorizes revisions to fact sheets to address SARS-CoV-2 variants fo
products unde Fact sheet for the alternative for the alternative for the step of the step of the step of the step of the step of
FDA authorizes revisions to fact sheets to address SARS-CoV-2 variants for monoclonal antibody
products und FDA authorizes revisions to fact sheets to address SARS-CoV-2 variants
products under emergency use authorization. Accessed online at https
safety-and-availability/fda-authorizes-revisions-fact-sheets-address-sar
antibodyproducts under emergency use authorization. Accessed online at https://www.fda.gov/drugs/dr
safety-and-availability/fda-authorizes-revisions-fact-sheets-address-sars-cov-2-variants-monoclo
antibody-products-
under#:~:text=

D on February 22, 2023.

Regeneron Ireland DAC use of casirivimab and imdevimab for the treatment of COVID-19.

J. Ai, X. Wang, X. He <u>D</u> on February 22, 2023.
<u>D</u> on February 22, 2023.
Regeneron Ireland DAC use of casirivimab and imdevimab for the treatment of COVID-19.
J. Ai, X. Wang, X. He, X. Zhao, Y. Zhang, Y. Jiang, M. Li, Y. Cui, Y. Chen, R. Qiao, —
Regeneron Ireland DAC L
J. Ai, X. Wang, X. He, X. Z
Zhang and P. Wang, Anti
Cell host & microbe **30** (2 J. Ai, X. Wang, X. He, X. Zhao, Y. Zhang, Y. Jiang, M. Li, Y. Cui, Y. Chen, R. Qiao, L. Li, L. Yang,
Zhang and P. Wang, Antibody evasion of SARS-CoV-2 Omicron BA.1, BA.1.1, BA.2, and BA.3
Cell host & microbe **30** (2022), Zhang and P. Wang, Antibody evasion of SARS-CoV-2 Omicron BA.1, BA.1.1, BA.2, and BA.3 sub-lineages, Cell host & microbe 30 (2022), pp. 1077-1083.e1074.

CoV-2 Monoclonal Antibodies After US Food and Drug Administration Deauthorization, JAMA Network
Open 5 (2022), pp. e2228997-e2228997. T.S. Anderson, A. O'Donoghue, O. Mechanic, T. Dechen and J. Stevens, Administration of Anti-SARS-

Esperalba, N. Saubi, J. Quer, A. Rando-Segura, M. Miarons, M.G. Codina, I. Ruiz-Camps, T. Pumarola, Cov-2 Monoclonal Antibodies After US Food and Drug Administration Deauthorization, JAMA Network
Open **5** (2022), pp. e2228997-e2228997.
C. Andrés, A. González-Sánchez, M. Jiménez, E. Márquez-Algaba, M. Piñana, C. Fernández C. Andrés, A. González-Sánchez, M. Jiménez, E. Márquez-Algaba, M. Piñana, C. Fernández-Naval, J.
Esperalba, N. Saubi, J. Quer, A. Rando-Segura, M. Miarons, M.G. Codina, I. Ruiz-Camps, T. Pumarola,
Abrisqueta and A. Antón, C. Andrés, M. Saubi, J. Quer, A. Rando-Segura, M. Miarons, M.G. Codina, I. Ruiz-Camps, T. Pumarola
Abrisqueta and A. Antón, Emergence of Delta and Omicron variants carrying resistance-associated
mutations in immunocompromi Esperalab, M. Saudy, M. Sauby, M. Hamer Legate, A. Rando-Ry, M. Pumaroly, A. Rando-Ry, A. Rando-Ry, A. Rando-R
Abrisqueta and A. Antón, Emergence of Delta and Omicron variants carrying resistance-associated
mutations in im Matriciple and A. Anti-Roman and A. Anti-Polisian and Polisian and A. Antations in immunocompromised patients undergoing sotrovimab treatment with long-term vira excretion, *Clinical Microbiology and Infection* 29 (2023),

mutation, *Clinical Microbiology and Infection* 29 (2023), pp. 240-246.
M.K. Annavajhala, H. Mohri, P. Wang, M. Nair, J.E. Zucker, Z. Sheng, A. Gomez-Simmonds, A.L. Kelley
Tagliavia, Y. Huang, T. Bedford, D.D. Ho and A.-C. excretion, C*linical Microbiology and Infection 29 (2023)*, pp. 240-246.
M.K. Annavajhala, H. Mohri, P. Wang, M. Nair, J.E. Zucker, Z. Sheng, A
Tagliavia, Y. Huang, T. Bedford, D.D. Ho and A.-C. Uhlemann, Emerger
B.1.526 a Tagliavia, Y. Huang, T. Bedford, D.D. Ho and A.-C. Uhlemann, Emergence and expansion of SARS-CoV-2
B.1.526 after identification in New York, *Nature* 597 (2021), pp. 703-708.
A. Baum, B.O. Fulton, E. Wloga, R. Copin, K.E.

B.1.526 after identification in New York, *Nature* 597 (2021), pp. 703-708.
A. Baum, B.O. Fulton, E. Wloga, R. Copin, K.E. Pascal, V. Russo, S. Giordano, K. Lanza, N. Negron, M. Ni, '
Wei, G.S. Atwal, A.J. Murphy, N. Stahl B.1.526 after identification in New York, Mature 337 (2021), pp. 703-708.
A. Baum, B.O. Fulton, E. Wloga, R. Copin, K.E. Pascal, V. Russo, S. Giordano
Wei, G.S. Atwal, A.J. Murphy, N. Stahl, G.D. Yancopoulos and C.A. Kyrat A. Baum, B.O. Fulton, A. Baum, B., A. Baum, A. Baum, A. Baum, A. Baum, A. Baum, A. Baum, A. Wei, G.S. Atwal, A.J. Murphy, N. Stahl, G.D. Yancopoulos and C.A. Kyratsous, Antibody cocktail to SARS-
CoV-2 spike protein preven

Development of Resistance-Associated Mutations After Sotrovimab Administration in High-risk Cov-2 spike protein prevents rapid mutational escape seen with mulvidual antibodies, 309 (2020), pp.
1014-1018.
E. Birnie, J.J. Biemond, B. Appelman, G.J. de Bree, M. Jonges, M.R.A. Welkers and W.J. Wiersinga,
Development E. Birnie, J.J.
Developmer
Individuals I
J. Boucau, K E. Emma, Internative, Entipperman, The Enternative Prontingal, Internative Individuals Infected With the SARS-CoV-2 Omicron Variant, Jama **328** (2022), pp. 1104-1107.
Individuals Infected With the SARS-CoV-2 Omicron Varian

Development of Resistance-Associated Mutation Carlier, Jama 328 (2022), pp. 1104-1107.
D. Boucau, K.W. Chew, M.C. Choudhary, R. Deo, J. Regan, J.P. Flynn, C.R. Crain, M.D. Hughes, J. R.
Moser, J.A. Dragavon, A.C. Javan, A. Individuals Infected With the SARS-Cov-2 Omicron Variant, Jama 328 (2022), pp. 1104-1107.
I. Boucau, K.W. Chew, M.C. Choudhary, R. Deo, J. Regan, J.P. Flynn, C.R. Crain, M.D. Hughes, J
Moser, J.A. Dragavon, A.C. Javan, A. Moser, J.A. Dragavon, A.C. Javan, A. Nirula, P. Klekotka, A.L. Greninger, R.W. Coombs, W.A. Fischer, E.S.
Daar, D.A. Wohl, J.J. Eron, J.S. Currier, D.M. Smith, J.Z. Li and A.K. Barczak, Monoclonal antibody
treatment drives Moser, J.A. Pragavon, Moseran, A. M. Man, J. S. Manney, A. M. J. S. Hanney, A. M. Postman, A. N. D. J. J.
Daar, D.A. Wohl, J.J. Eron, J.S. Currier, D.M. Smith, J.Z. Li and A.K. Barczak, Monoclonal antibody
treatment drives Daar, Daar, Daar, Division, J.J. Eron, J.J. Eron, J.J. D.A. Barczak, M.A. D.A. Barcament drives rapid culture conversion in SARS-CoV-2 infection, *Cell Reports Medicine* 3 (2022)
100678.
Y. Bronstein, A. Adler, H. Katash,

treatment drives rapid culture conversion in SARS-CoV-2 infection, c*ell Reports Medicine* 3 (2022), p.
100678.
Y. Bronstein, A. Adler, H. Katash, O. Halutz, H. Y and K. Levytskyi, Evolution of spike mutations followir
ant Y. Bronst
antibody
medical
Y. Cao, F antibody treatment in two immunocompromised patients with persistent COVID-19 infection, *Journal of*
medical virology (2021).
Y. Cao, F. Jian, J. Wang, Y. Yu, W. Song, A. Yisimayi, J. Wang, R. An, N. Zhang, Y. Wang, P.

antibody treatment in two immunocompromised patients with persistent COVID-19 infection, Journal of
medical virology (2021).
Y. Cao, F. Jian, J. Wang, Y. Yu, W. Song, A. Yisimayi, J. Wang, R. An, N. Zhang, Y. Wang, P. Wang medical virology (2021).
Y. Cao, F. Jian, J. Wang, Y
H. Sun, L. Yu, S. Yang, X. I Y. Carry Winny P. Hiang, Y. Wang, Y. Perng, P. Perng, P. Perng, P. Perng, P. Perng, P. Perng, P. Perng, 2. 2h
H. Sun, L. Yu, S. Yang, X. Niu, T. Xiao, Q. Gu, F. Shao, X. Hao, Y. Xu, R. Jin, Y. Wang and X.S. Xie, Imprinted
 H and $\frac{1}{4}$ and $\frac{1}{4}$ and $\frac{1}{4}$ and $\frac{1}{4}$ and $\frac{1}{4}$ and $\frac{1}{4}$

SARS-CoV-2 humoral immunity madees convergent Omicron RBD evolution, Nuture (2022), p.
2022.2009.2015.507787.
A. Casadevall and D. Focosi, SARS-CoV-2 variants resistant to monoclonal antibodies in
immunocompromised patient -
- A. Casadevall and D. Foco
immunocompromised pat
A.L. Cathcart, C. Havenar-
L. Rosen, H. Tucker, J. Dill immunocompromised patients is a public health concern, *The Journal of clinical investig*
A.L. Cathcart, C. Havenar-Daughton, F.A. Lempp, D. Ma, M. Schmid, M.L. Agostini, B. Gu
L. Rosen, H. Tucker, J. Dillen, S. Subramania immunocompromised patients is a public health concern, *The Soumar of eimicu investigation (*2023).
A.L. Cathcart, C. Havenar-Daughton, F.A. Lempp, D. Ma, M. Schmid, M.L. Agostini, B. Guarino, J. Di iuli
L. Rosen, H. Tucke A. L. Rosen, H. Tucker, J. Dillen, S. Subramanian, B. Sloan, S. Bianchi, J. Wojcechowskyj, J. Zhou, H. Kaiser, A
Chase, M. Montiel-Ruiz, N. Czudnochowski, E. Cameroni, S. Ledoux, C. Colas, L. Soriaga, A. Telenti, S.
Hwang, L. Rosen, M. Pathel, Y. P. L. Rosen, J. D. L. Rosen, J. P. L. Rosen, J. P. P. L. Rosen, A. Telenti, S.
Chase, M. Montiel-Ruiz, N. Czudnochowski, E. Cameroni, S. Ledoux, C. Colas, L. Soriaga, A. Telenti, S.
Hwang, G. Snell, Hwang, G. Snell, H.W. Virgin, D. Corti and C.M. Hebner, The dual function monoclonal antibodies VIR-7832 demonstrate potent in vitro and in vivo activity against SARS-CoV-2, (2021), p.
2021.2003.2009.434607.

globally shared SARS-CoV-2 data to identify and characterize new variants, Bioinformatics 38 (2021a), pp. C. Chen, S. Nadeau, M. Yared, P. Voinov, N. Xie, C. Roemer and T. Stadler, CoV-Spectrum: analysis of globally shared SARS-CoV-2 data to identify and characterize new variants, *Bioinformatics* 38 (2021a
1735-1737. 2021.2003.2009.434607. C. Chen, S. Nadaler, S. Nadeau, S.
1735-1737.
R.E. Chen, X. Zhang, J.B. Case, E.S. Winkler, Y. Liu, L.A. VanBlargan, J. Liu, J.M. Errico, X. Xie,

globally shared SARS-Cov-2 data to identify and characterize new variants, *Biomjormatics* 38 (2021a), pp.
1735-1737.
R.E. Chen, X. Zhang, J.B. Case, E.S. Winkler, Y. Liu, L.A. VanBlargan, J. Liu, J.M. Errico, X. Xie, N.
S R.E. Chen, X
Suryadevara
A.C.M. Boor
Corti, H.W. [\] Suryadevara, P. Gilchuk, S.J. Zost, S. Tahan, L. Droit, J.S. Turner, W. Kim, A.J. Schmitz, M. Thapa
A.C.M. Boon, R.M. Presti, J.A. O'Halloran, A.H.J. Kim, P. Deepak, D. Pinto, D.H. Fremont, J.E. Cr
Corti, H.W. Virgin, A.H. Suryadevara, P. G. Gilchum, S. G. Gilchum, S. T. P. B. Stephen, P. G. B. G. G.M. Boon, R.M. Presti, J.A. O'Halloran, A.H.J. Kim, P. Deepak, D. Pinto, D.H. Fremont, J.E. Crowe, Jr., D.
Corti, H.W. Virgin, A.H. Ellebedy, P.Y A.C.M. Boon, R.M. Presti, J.A. O'Halloran, A.H.J. Kim, P. Deepak, D. Pinto, D.H. Fremont, J.E. Crowe, Jr., D.
Corti, H.W. Virgin, A.H. Ellebedy, P.Y. Shi and M.S. Diamond, Resistance of SARS-CoV-2 variants to
neutralizatio Corti, H.W. Virgin, A.H. Ellebedy, P.Y. Shi and M.S. Diamond, Resistance of SARS-CoV-2 variants to
neutralization by monoclonal and serum-derived polyclonal antibodies, Nat Med 27 (2021b), pp. 717-
726.

neutralization by monoclonal and serum-derived polycional antibodies, Nat Med 27 (2021b), pp. 717
726.
B. Choi, M.C. Choudhary, J. Regan, J.A. Sparks, R.F. Padera, X. Qiu, I.H. Solomon, H.-H. Kuo, J. Boucau,
Bowman, U.D. A B. Ch
Bowr
Walk
Barcz Bowman, U.D. Adhikari, M.L. Winkler, A.A. Mueller, T.Y.-T. Hsu, M. Desjardins, L.R. Baden, B.T. Chan, B.D. Walker, M. Lichterfeld, M. Brigl, D.S. Kwon, S. Kanjilal, E.T. Richardson, A.H. Jonsson, G. Alter, A.K. Barczak, W. Malker, M. Lichterfeld, M. Brigl, D.S. Kwon, S. Kanjilal, E.T. Richardson, A.H. Jonsson, G. Alter, A.K.
Barczak, W.P. Hanage, X.G. Yu, G.D. Gaiha, M.S. Seaman, M. Cernadas and J.Z. Li, Persistence and
Evolution of SARS-CoV

Manczak, W.P. Hanage, X.G. Yu, G.D. Gaiha, M.S. Seaman, M. Cernadas and J.Z. Li, Persistence and
Evolution of SARS-CoV-2 in an Immunocompromised Host, 383 (2020), pp. 2291-2293.
M.C. Choudhary, K.W. Chew, R. Deo, J.P. Flyn Evolution of SARS-CoV-2 in an Immunocompromised Host, 383 (2020), pp. 2291-2293.
M.C. Choudhary, K.W. Chew, R. Deo, J.P. Flynn, J. Regan, C.R. Crain, C. Moser, M.D. Hughes, J. Ritz
Ribeiro, R. Ke, J.A. Dragavon, A.C. Javan Evolution of SARS-Cov-2 in an Immunocompromised Host, 383 (2020), pp. 2231-2233.
M.C. Choudhary, K.W. Chew, R. Deo, J.P. Flynn, J. Regan, C.R. Crain, C. Moser, M.D. Hug
Ribeiro, R. Ke, J.A. Dragavon, A.C. Javan, A. Nirula, Ribeiro, R. Ke, J.A. Dragavon, A.C. Javan, A. Nirula, P. Klekotka, A.L. Greninger, C.V. Fletcher, E.S. Daar,
D.A. Wohl, J.J. Eron, J.S. Currier, U.M. Parikh, S.F. Sieg, A.S. Perelson, R.W. Coombs, D.M. Smith, J.Z. Li, D
Sm D.A. Wohl, J.J. Eron, J.S. Currier, U.M. Parikh, S.F. Sieg, A.S. Perelson, R.W. Coombs, D.M. Smith, J.Z. Li,
Smith, A.C. Javan, M. Giganti, L. Hosey, J. Roa, N. Patel, K. Colsh, I. Rwakazina, J. Beck, S. Sieg, W. Fisch
T. Smith, A.C. Javan, M. Giganti, L. Hosey, J. Roa, N. Patel, K. Colsh, I. Rwakazina, J. Beck, S. Sieg, W. Fischer,
T. Evering, R.B. Ignacio, S. Cardoso, K. Corado, P. Jagannathan, N. Jilg, S. Pillay, C. Riviere, U. Singh, B. Smith, A.C. Denter, A.C. Deptember, A.C. Deptember, A.C. Deptember, A.C. Horing, R. B. J. Singh, B.
T. Evering, R.B. Ignacio, S. Cardoso, K. Corado, P. Jagannathan, N. Jilg, S. Pillay, C. Riviere, U. Singh, B.
Taiwo, J. Go Taiwo, J. Gottesman, M. Newell, S. Pedersen, J. Dragavon, C. Jennings, B. Greenfelder, W. Murtaugh, Kosmyna, M. Gapara, A. Shahkolahi and A.-A.S.T. for the, Emergence of SARS-CoV-2 escape mutation
during Bamlanivimab thera Kosmyna, M. Gapara, A. Shahkolahi and A.-A.S.T. for the, Emergence of SARS-CoV-2 escape mutations
during Bamlanivimab therapy in a phase II randomized clinical trial, *Nature Microbiology* **7** (2022), pp.
1906-1917.
S.A. C during Bamlanivimab therapy in a phase II randomized clinical trial, *Nature Microbiology* 7 (2022), pp.
1906-1917.
S.A. Clark, L.E. Clark, J. Pan, A. Coscia, L.G.A. McKay, S. Shankar, R.I. Johnson, V. Brusic, M.C. Choudha

during Bamlanivimab therapy in a phase in andomized clinical trial, *Nuture Microbiology 7* (2022), pp.
1906-1917.
S.A. Clark, L.E. Clark, J. Pan, A. Coscia, L.G.A. McKay, S. Shankar, R.I. Johnson, V. Brusic, M.C. Choudhar --------
S.A. Clark, L.
Regan, J.Z. L
shared neut
R. Copin, A. Regan, J.Z. Li, A. Griffiths and J. Abraham, SARS-CoV-2 evolution in an immunocompromised host reveals shared neutralization escape mechanisms, Cell 184 (2021), pp. 2605-2617.e2618.
R. Copin, A. Baum, E. Wloga, K.E. Pascal

shared neutralization escape mechanisms, *Cell* **184** (2021), pp. 2605-2617.e2618.
R. Copin, A. Baum, E. Wloga, K.E. Pascal, S. Giordano, B.O. Fulton, A. Zhou, N. Negron, K. Lanza, N. Chan,
A. Coppola, J. Chiu, M. Ni, G.S. shared neutralization escape incenamsins, een 184 (2021), pp. 2005-2017. (2016.
R. Copin, A. Baum, E. Wloga, K.E. Pascal, S. Giordano, B.O. Fulton, A. Zhou, N. Negi
A. Coppola, J. Chiu, M. Ni, G.S. Atwal, A. Romero Hernand Somersan-Karakaya, S. Sivapalasingam, G.A. Herman, D.M. Weinreich, L. Lipsich, N. Stahl, A.J. Murphy, G.D. Yancopoulos and C.A. Kyratsous, The monoclonal antibody combination REGEN-COV protects Morper, S. McCarthy, S. Hamon, J.D. Hamilton, H.M. Staples, K. Alfson, R. Carrion, S. Ali, T. Norton, S.
Bomersan-Karakaya, S. Sivapalasingam, G.A. Herman, D.M. Weinreich, L. Lipsich, N. Stahl, A.J. Murph
G.D. Yancopoulos Somersan-Karakaya, S. Sivapalasingam, G.A. Herman, D.M. Weinreich, L. Lipsich, N. Stahl, A.J. Murphy
G.D. Yancopoulos and C.A. Kyratsous, The monoclonal antibody combination REGEN-COV protects
against SARS-CoV-2 mutational G.D. Yancopoulos and C.A. Kyratsous, The monoclonal antibody combination REGEN-COV protects
against SARS-CoV-2 mutational escape in preclinical and human studies, *Cell* 184 (2021), pp. 3949-3961
G. Destras, S. Assaad, A. against SARS-CoV-2 mutational escape in preclinical and human studies, *Cell* **184** (2021), pp. 3949-3
G. Destras, S. Assaad, A. Bal, M. Bouscambert-Duchamp, V. Avrillon, B. Simon, M. Valette, J.-Y. Blay
Lina, E. Frobert a against SARS-Cov-2 mutational escape in preclimear and human studies, Cell 184 (2021), pp. 3949-3961.
G. Destras, S. Assaad, A. Bal, M. Bouscambert-Duchamp, V. Avrillon, B. Simon, M. Valette, J.-Y. Blay, B.
Lina, E. Frober G. Destras, S. Assays, M. Box, M. Boussiller, Channel, Channel, Channel, Antenney, M. P. 2017, D.
Lina, E. Frobert and L. Josset, Bamlanivimab as monotherapy in two immunocompromised patients wit
G. Destras, A. Bal, B. Sim

Lina, E. Frobert and L. Joseph Andreas Microbert and L. Joseph Andreas Patients with COVID-19, The Lancet Microbe 2 (2021), p. e424.
G. Destras, A. Bal, B. Simon, B. Lina and L. Josset, Sotrovimab drives SARS-CoV-2 Omicron COVID-19, The Lancet Microbe 2 (2021), p. e424.
G. Destras, A. Bal, B. Simon, B. Lina and L. Josset,
evolution in immunocompromised patients, The I evolution in immunocompromised patients, *The Lancet. Microbe* **3** (2022), p. E559.
15 evolution in immunocompromised patients, The Lancet. Microbe 3 (2022), p. E559.

W. Du, D.L. Hurdiss, D. Drabek, A.Z. Mykytyn, F. Kaiser, M. Gonzalez-Hernandez, D. Munoz-Santos, M.M.
Lamers, R. van Haperen, W. Li, I. Drulyte, C. Wang, I. Sola, F. Armando, G. Beythien, M. Ciurkiewicz, W.
Baumgartner, K. broad neutralization and protection against Omicron and other SARS-CoV-2 variants, (2022), p.
2022.2002.2017.480751. Haagmans, L. Enjuanes, A.D. Osterhaus, F. Grosveld and B.J. Bosch, An ACE2-blocking antibody co
broad neutralization and protection against Omicron and other SARS-CoV-2 variants, (2022), p.
2022.2002.2017.480751.
EMA, Eli broad neutralization and protection against Omicron and other SARS-CoV-2 variants, (2022), p.
2022.2002.2017.480751.
EMA, Eli Lilly and Company Limited use of bamlanivimab and etesevimab for the treatment of COVID-1:
(2021

broad neutralization and protection against Omicron and Omicron and Octomana, (2022)
1922.2002.2017.480751.
EMA, Eli Lilly and Company Limited use of bamlanivimab and etesevimab for the treatment of Co.
L. Fabeni, C.E. Gru -
EMA, Eli Lilly and Compar
(2021).
L. Fabeni, C.E. Gruber, F. 1
Focosi, E. Nicastri, E. Giraı

EMA, Eliam, Eliam, Eliam, Eliam and Company Limited use of an establishment of the treatment of Company
L. Fabeni, C.E. Gruber, F. Tucci, V. Mazzotta, M. Rueca, G. Gramigna, A. Vergori, E. Giombini, O. Butera, D.
Focosi, E `
L. Faber
Focosi,
resistan
FDA, Fa Focosi, E. Nicastri, E. Girardi, F. Vaia, A. Antinori and F. Maggi, Treatment-emergent cilgavimab
resistance in Omicron BA.4/5, *Drug Resistance Updates* (2023).
FDA, Fact sheet for healthcare providers: emergency use aut

Focosy at the anti-principly and the ligation of the ligation of the ligation of the ligation of the ligavity resistance in Omicron BA.4/5, *Drug Resistance Updates* (2023).
FDA, Fact sheet for healthcare providers: emerg resistance in Omicron BA.4/5, *Brug Resistance Opdates* (2023).
FDA, Fact sheet for healthcare providers: emergency use author
packaged with cilgavimab). Accessed online at <u>https://www.fda</u>
February 3, 2023, (2021).
FDA,

https://www.fda.gov/drugs/drug-safety-and-availability/fda-authorizes-revisions-evusheld-dosing, packaged with circuit circuit circuit circuit controlled with the behavior of the behavior of the behavior of
PDA, FDA authorizes revisions to Evusheld dosing. Accessed online on April 29, 2022 at
https://www.fda.gov/drugs FDA, FDA authorizes revisi
https://www.fda.gov/drug
(2022).
FDA, FDA authorizes revisi Forty Particular Present Present Review and Security Present Present Present Attps://www.fda.gov/drugs/drug-safety-and-availability/fda-authorizes-revisions-evush
(2022).
FDA, FDA authorizes revisions to fact sheets to add

https://www.fda.gov/drugs/drug-safety-and-availability/fida-authorizets-revisions-fact-sheets SARS-CoV-2 variants for monoclonal antibod
products under emergency use authorization. Accessed online at https://www.fda.gov/dr (-----)
FDA, FD
product
safety-a
antibod products under emergency use authorization. Accessed online at https://www.fda.gov/drugs/drug-

safety-and-availability/fda-authorizes-revisions-fact-sheets-address-sars-cov-2-variants-monoclonal-

antibody-products-under

genomic surveillance, submitted (2023).

D. Focosi, S. McConnell, A. Casadevall, E. Cappello, G. Valdiserra and M. Tuccori, Monoclonal antibody D. Focosi, A web tool to estimate baaseline anti-
genomic surveillance, *submitted* (2023).
D. Focosi, S. McConnell, A. Casadevall, E. Cappel
therapies against SARS-CoV-2, *The Lancet Infect* Benomic surveillance, *submitted* (2023).
D. Focosi, S. McConnell, A. Casadevall, E. Cappello, G. Valdiserra and M. Tuccori, Monoclonal antibody
therapies against SARS-CoV-2, *The Lancet Infectious Diseases* 22 (2022a), pp genomic surveillance, submitted (2023).
D. Focosi, S. McConnell, A. Casadevall, E.
therapies against SARS-CoV-2, *The Lance*
D. Focosi, F. Novazzi, A. Baj, F.D. Ferrante
Sotrovimab-emergent resistance in SARS

Therapies against SARS-CoV-2, The Lancet Infectious Diseases 22 (2022a), pp. 00311-00315.
D. Focosi, F. Novazzi, A. Baj, F.D. Ferrante, S. Boutahar, A.P. Genoni, D.D. Gasperina and F. Maggi,
Sotrovimab-emergent resistance therapies against SARS-Cov-2, *The Lancet Infectious Diseases 22 (2022a)*, pp. 00311-00315.
D. Focosi, F. Novazzi, A. Baj, F.D. Ferrante, S. Boutahar, A.P. Genoni, D.D. Gasperina and F. N
Sotrovimab-emergent resistance in Sotrovimab-emergent resistance in SARS-CoV-2 Omicron: A series of three cases, *J Clin Virol Plus 2*
(2022b), p. 100097.
D. Focosi, F. Novazzi, A. Genoni, F. Dentali, D. Dalla Gasperina, A. Baj and F. Maggi, Daniele Focosi

Sotrovimab-emergent resistance in SARS-Cov-2 Omicron: A series of three cases, J C*lin Virol Pus 2*
(2022b), p. 100097.
D. Focosi, F. Novazzi, A. Genoni, F. Dentali, D. Dalla Gasperina, A. Baj and F. Maggi, Daniele Focosi, (2022), p. 20000
D. Focosi, F. Novazzi
Federica Novazzi, Ar
Maggi, (2021).
D. Focosi, R. Quiroga D. Focosi, F. Novazzi, Angelo Genoni, Francesco Dentali, Daniela Dalla gasperina, Andreina Baj, Fabrizio
Maggi, (2021).
D. Focosi, R. Quiroga, S. McConnell, M.C. Johnson and A. Casadevall, Convergent evolution in SARS
2 Sp

Maggi, (2021).
D. Focosi, R. Quiroga, S. McConnell, M.C. Johnson and A. Casadevall, Convergent evolution in SARS-0
2 Spike creates a variant soup from which new COVID-19 waves emerge, International Journal of
Molecular Sci D. Focosi, R. Qu
2 Spike creates
Molecular Scien
D. Focosi and M

Resistant SARS-CoV-2 Variants in Italy, Pathogens (Basel, Switzerland) 11 (2022). 2 Spike creates a variant soup from which new COVID-15 waves emerge, *international sournal of*
Molecular Sciences **24** (2023), p. 2264.
D. Focosi and M. Tuccori, Prescription of Anti-Spike Monoclonal Antibodies in COVID-1

Molecului Sciences 24 (2023), p. 2204.
D. Focosi and M. Tuccori, Prescription of
Resistant SARS-CoV-2 Variants in Italy,
S. Gliga, N. Luebke, A. Killer, H. Gruell, J
J.G. Bode, F. Klein, J. Timm, T. Luedde a Resistant SARS-CoV-2 Variants in Italy, *Pathogens (Basel, Switzerland)* **11** (2022).
S. Gliga, N. Luebke, A. Killer, H. Gruell, A. Walker, A.T. Dilthey, C. Lohr, C. Flaßhove, H.M. Orth, T. Feldt,
J.G. Bode, F. Klein, J. T Resistant SARS-CoV-2 Variants in Italy, Pathogens (Baser, Switzerland) 11 (2022).
S. Gliga, N. Luebke, A. Killer, H. Gruell, A. Walker, A.T. Dilthey, C. Lohr, C. Flaßhov
J.G. Bode, F. Klein, J. Timm, T. Luedde and B.O. Jen J.G. Bode, F. Klein, J. Timm, T. Luedde and B.O. Jensen, Rapid selection of sotrovimab escape variants ir
SARS-CoV-2 Omicron infected immunocompromised patients, *Clinical Infectious Diseases* (2022).
R.L. Gottlieb, A. Nir

J. B. Bode, F. Antany, F. Klein, J. Batania and Bottomics, Ample Station Infectious Diseases (2022).
SARS-CoV-2 Omicron infected immunocompromised patients, *Clinical Infectious Diseases* (2022).
R.L. Gottlieb, A. Nirula, SARS-Cov-2 Omicron infected immunocompromised patients, *chincui infectious Diseases (2022).*
R.L. Gottlieb, A. Nirula, P. Chen, J. Boscia, B. Heller, J. Morris, G. Huhn, J. Cardona, B. Mocherla, V.
I. Shawa, P. Kumar, A.C

l. Shawa, P. Kumar, A.C. Adams, J. Van Naarden, K.L. Custer, M. Durante, G. Oakley, A.E. Schade, T.R.
Holzer, P.J. Ebert, R.E. Higgs, N.L. Kallewaard, J. Sabo, D.R. Patel, P. Klekotka, L. Shen and D.M.
Skovronsky, Effect o Holzer, P.J. Ebert, R.E. Higgs, N.L. Kallewaard, J. Sabo, D.R. Patel, P. Klekotka, L. Shen and D.M.
Skovronsky, Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Loa
in Patients With Mild to Skovronsky, Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Vi
in Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial, JAMA 325 (2021), p
A.J. Greaney, A.N. Loes, K.H. Crawford, in Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial, JAMA 325 (2021), pp. 632-644.
A.J. Greaney, A.N. Loes, K.H. Crawford, T.N. Starr, K.D. Malone, H.Y. Chu and J.D. Bloom, Comprehensive
mapping of muta A.J. Greaney, A.N. Loes, K.H. Crawford, T.N. Starr, K.D. Malone, H.Y. Chu and J.D. Bloom, Comprehensive mapping of mutations to the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal man serum antibodies, *bioRxiv [Preprint]* (2021).
16 human serum antibodies, bionary μ reprint] (2021).

A. Buigon, E. Faure, P. Bennins, Antenephi, Bennies, Antenephi, M. Barton, J. P. Bennies, A.
Engelmann and E. Kazali Alidjinou, Emergence of Q493R mutation in SARS-CoV-2 spike protein
bamlanivimab/etesevimab treatment and Engelmann and Economy and Same Congress of Q1931 mathematics in Engels (20163-4453 (2021), pp
D0435-00437.
A. Gupta, A. Konnova, M. Smet, M. Berkell, A. Savoldi, M. Morra, V. Van Averbeke, F. De Winter, D.
Peserico, E. Dan

bamlanivimab, etesevimab treatment and resistance to viral clearance, J mject 50103-4453 (2021), pp.
00435-00437.
A. Gupta, A. Konnova, M. Smet, M. Berkell, A. Savoldi, M. Morra, V. Van Averbeke, F. De Winter, D.
Peserico, A. Gupta, A. Ko
Peserico, E. Da
Kumar and S. I
mutations in p Peserico, E. Danese, A. Hotterbeekx, E. Righi, m.O.w. group, P. De Nardo, E. Tacconellil, S. Malhotra-
Kumar and S. Kumar-Singh, Host immunological responses facilitate development of SARS-CoV-2 2
mutations in patients rec mutations in patients receiving monoclonal antibody treatments, The Journal of clinical investigation

.
P.J. Halfmann, N.R. Minor, L.A. Haddock III, R. Maddox, G.K. Moreno, K.M. Braun, D.A. Baker, K.K.
Riemersa, A. Prasad, K.J. Alman, M.C. Lambert, K. Florek, A. Bateman, R. Westergaard, N. Safdar, D.F
Andes, Y. Kawaoka, M. mutations in patients receiving monoclonal antibody treatments, *The Sournar of eilinear investigation*
(2023).
P.J. Halfmann, N.R. Minor, L.A. Haddock III, R. Maddox, G.K. Moreno, K.M. Braun, D.A. Baker, K.K.
Riemersa, A. P. Halfmann, J. Halfmann, J. Halfmann, H. Halfmann, H. Halfmann, H. Halfmann, H. Halfmann, N. Safdar, I.
Riemersa, A. Prasad, K.J. Alman, M.C. Lambert, K. Florek, A. Bateman, R. Westergaard, N. Safdar, I.
SARS-CoV-2 Spike Riemers, A. Prassa, M. Primmar, A. Prasadis, A. Prassad, A. Bateman, A. Pressing, A. Pressin, A. Prassa, 2006
Andes, Y. Kawaoka, M. Fida, J.D. Yao, T.C. Friedrich and D.H. O'Connor, Evolution of a globally unique
SARS-CoV-SARS-CoV-2 Spike E484T monoclonal antibody escape mutation in a persistently infected,
immunocompromised individual, *Virus Evolution* (2022).
K. Harman, S.G. Nash, H.H. Webster, N. Groves, J. Hardstaff, J. Bridgen, P.B. B

immunocompromised individual, *Virus Evolution* (2022).
K. Harman, S.G. Nash, H.H. Webster, N. Groves, J. Hardstaff, J. Bridgen, P.B. Blomquist, R. I
Ashano, R. Myers, S. Rokadiya, S. Hopkins, C.S. Brown, M. Chand, G. Dabr Immunocompromised marvidual, *Virus Evolution* (2022).
K. Harman, S.G. Nash, H.H. Webster, N. Groves, J. Hardsta
Ashano, R. Myers, S. Rokadiya, S. Hopkins, C.S. Brown, M
Comparison of the risk of hospitalisation among BA.1 Ashano, R. Myers, S. Rokadiya, S. Hopkins, C.S. Brown, M. Chand, G. Dabrera and S. Thelwall,
Comparison of the risk of hospitalisation among BA.1 and BA.2 COVID-19 cases treated with Sotrov
in the community in England, (20 Comparison of the risk of hospitalisation among BA.1 and BA.2 COVID-19 cases treated with Sotrovimab

Comparison of the risk of hospitalisation b
M. Hoffmann, L. Zhang, N. Krüger, L. Graichen, H. Kleine-Weber, H. Hofmann-Winkler, A. Kempf, S.
Nessler, in mink reduce antibody-mediated neutralization, (2021) , p. 2021.2002.2012.430998. Nessler, J. Riggert, M.S. Winkler, S. Schulz, H.-M. Jäck and S. Pöhlmann, SARS-CoV-2 mutations acqu
in mink reduce antibody-mediated neutralization, (2021), p. 2021.2002.2012.430998.
R.V. House, T.A. Broge, T.J. Suscovich,

Nessler, J. Riggert, M. R. Rimmar, J. P. Burma, M. M. Rimsell and S. 2021.2002.2012.430998.
In mink reduce antibody-mediated neutralization, (2021), p. 2021.2002.2012.430998.
R.V. House, T.A. Broge, T.J. Suscovich, D.M. Sn IN MINITERT PINN REDUCE AND MINITERTY, (2022), p. 2022. Nonet, K. Bajwa, G. Z.
Hackett, C.G. Earnhart, N.M. Dorsey, S.A. Hopkins, D.S. Natour, H.D. Davis, M.S. Anders
and R.R. Cobb, Evaluation of strategies to modify Anti-Hackett, C.G. Earnhart, N.M. Dorsey, S.A. Hopkins, D.S. Natour, H.D. Davis, M.S. Anderson, M.R. Gainey
and R.R. Cobb, Evaluation of strategies to modify Anti-SARS-CoV-2 monoclonal antibodies for optimal
functionality as th Hackett, Cobb, Evaluation of strategies to modify Anti-SARS-CoV-2 monoclonal antibodies for optimal
functionality as therapeutics, PloS one 17 (2022), p. e0267796.
S. Huygens, B.O. Munnink, A. Gharbharan, M. Koopmans and B

and R.R. Cobb, Example R.R. Cobb, R.R. Cobb, P.R. 2016-796.
S. Huygens, B.O. Munnink, A. Gharbharan, M. Koopmans and B. Rijnders, Sotrovimab resistance and v
persistence after treatment of immunocompromised patients infect functionality as therapeutics, *PloS one 17* (2022), p. e0267796.
S. Huygens, B.O. Munnink, A. Gharbharan, M. Koopmans and B.
persistence after treatment of immunocompromised patients i
variant, *Clinical Infectious Diseas* persistence after treatment of immunocompromised patients infected with the SARS-CoV-2 Omicron
variant, *Clinical Infectious Diseases* (2022).
S. Iketani, L. Liu, Y. Guo, L. Liu, Y. Huang, M. Wang, Y. Luo, J. Yu, M.T. Yin,

.
variant, *Clinical Infectious Diseases* (2022).
S. Iketani, L. Liu, Y. Guo, L. Liu, Y. Huang, M. Wang, Y. Luo, J. Yu, M.T. Yin, M.E. Sobieszczyk, Y. Huang, I
Wang, Z. Sheng and D.D. Ho, Antibody Evasion Properties of SAR variant, Chincul Infectious Diseases (2022).
S. Iketani, L. Liu, Y. Guo, L. Liu, Y. Huang, M.
Wang, Z. Sheng and D.D. Ho, Antibody Evas
604 (2022), pp. 553-556.
A. Jary, S. Marot, A. Faycal, S. Leon, S. Sayo S. Iketani, L. Liu, Y. Liu, Y. Liu, Y. Huang, M. Huang, H. Liu, I. M. M. M., M. L. L. L. L. L. L. L. L. M. Man
1998, Z. Sheng and D.D. Ho, Antibody Evasion Properties of SARS-CoV-2 Omicron Sublineages, *Nature*
1994, A. Ja

Wang, 2. Sheng and D.D. Ho, Antibody Evasion Properties of SARS-CoV-2 Omicron Submeages, Nuture
604 (2022), pp. 553-556.
A. Jary, S. Marot, A. Faycal, S. Leon, S. Sayon, K. Zafilaza, E. Ghidaoui, S.N. Quoc, S. Nemlaghi, S. **604** (2022), pp. 553-556.
A. Jary, S. Marot, A. Fayca
M. Dres, V. Pourcher, V. C
Escape Mutations in Patie
Antibodies Therapies, *Vir* M. Dres, V. Pourcher, V. Calvez, H. Junot, A.G. Marcelin and C. Soulié, Spike Gene Evolution and Immune
Escape Mutations in Patients with Mild or Moderate Forms of COVID-19 and Treated with Monoclonal
Antibodies Therapies, M. Dres, Wittermary, Withing, Wittermark and Creams, J. price Carl Creams in Andronian.
B. Jensen, N. Luebke, T. Feldt, V. Keitel, T. Brandenburger, D. Kindgen-Milles, M. Lutterbeck, N.F. Freise,
D. Schoeler, R. Haas, A. D

Antibodies Therapies, *Viruses* 14 (2022).
B. Jensen, N. Luebke, T. Feldt, V. Keitel, T. Brandenburger, D. Kindgen-Milles, M. Lutterbeck, N.F. Freise,
D. Schoeler, R. Haas, A. Dilthey, O. Adams, A. Walker, J. Timm and T. L The Lancet Regional Health - Europe 8 (2021). mutation in SARS-COV-2-infected immunocompromised patients treated with bamlanivimab in Germa
The Lancet Regional Health – Europe 8 (2021).
L. Liu, S. Iketani, Y. Guo, J.F.-W. Chan, M. Wang, L. Liu, Y. Luo, H. Chu, Y. Huan

L. Liu, S. Iketani, Y. Guo, J.F.-W. Chan, M. Wang, L. Liu, Y. Luo, H. Chu, Y. Huang, M.S. Nair, J. Yu, K.K.-H. mutation in Sarton in Same International and the U.S. Cover-2014.
The Lancet Regional Health – Europe 8 (2021).
L. Liu, S. Iketani, Y. Guo, J.F.-W. Chan, M. Wang, L. Liu, Y. Luo, H. Chu, Y. Huang, M.S. Nair, J. Yu, K.K.-H. The Lancet Regional Health – Europe **8** (2021).
L. Liu, S. Iketani, Y. Guo, J.F.-W. Chan, M. Wang
Chik, T.T.-T. Yuen, C. Yoon, K.K.-W. To, H. Chen
Sheng, K.-Y. Yuen and D.D. Ho, Striking Antiboc
CoV-2, (2021), p. 2021.2012 Chik, T.T.-T. Yuen, C. Yoon, K.K.-W. To, H. Chen, M.T. Yin, M.E. Sobieszczyk, Y. Huang, H.H. Wang, Z.
Sheng, K.-Y. Yuen and D.D. Ho, Striking Antibody Evasion Manifested by the Omicron Variant of SARS-
CoV-2, (2021), p. 20

Sheng, K.-Y. Yuen and D.D. Ho, Striking Antibody Evasion Manifested by the Omicron Variant of SARS-CoV-2, (2021), p. 2021.2012.2014.472719.
B. Lohr, D. Niemann and J. Verheyen, Bamlanivimab treatment leads to rapid selecti Infectious Diseases (2021). B. Lohr, D. Niemann and J. Verheyen, Bamlanivimab treatment leads to rapid selection of immune
escape variant carrying E484K mutation in a B.1.1.7 infected and immunosuppressed patient, Clinica
Infectious Diseases (2021).
 B. Longian Carry Constantino March, D. N. Niemann and D. Longian Carry Computers of Ammann and Secape variant carrying E484K mutation in a B.1.1.7 infected and immunosuppressed patient, *Clinic*
Infectious Diseases (2021).

escape variant carrying E484K mutation in a B.1.1.7 infected and immunosuppressed patient, emilear
Infectious Diseases (2021).
K.G. Nabel, S.A. Clark, S. Shankar, J. Pan, L.E. Clark, P. Yang, A. Coscia, L.G.A. McKay, H.H. Infectious Diseases (2021).
K.G. Nabel, S.A. Clark, S. Sh.
Brusic, N.V. Tolan, G. Zhou, Brusic, N.V. Tolan, G. Zhou, M. Desjardins, S.E. Turbett, S. Kanjilal, A.C. Sherman, A. Dighe, R.C. LaRor
17 Brusic, N.V. Tolan, G. Zhou, M. Desjardins, S.E. Turbett, S. Kanjila, A.C. Sherman, A. D. Greg, R.C. Larocque,
17

E.T. Ryan, E.T. Ryan, P.C. Charles and J. Abraham, Structural basis for continued antibody evasion by the SARS-CoV-2 receptor binding domain, 375 (2022), p. eabl6251.
SARS-CoV-2 receptor binding domain, 375 (2022), p. eabl

SARS-CoV-2 receptor binding domain, 375 (2022), p. eabl6251.
SARS-CoV-2 receptor binding domain, 375 (2022), p. eabl6251.
V. Patel, B. Levick, S. Boult, D.C. Gibbons, M. Drysdale, E.J. Lloyd, M. Singh and H.J. Birch, Chara SARS-COV-2 receptor binding domain, 375 (2022), p. eablozof.
V. Patel, B. Levick, S. Boult, D.C. Gibbons, M. Drysdale, E.J. Lloyd
and Outcomes of COVID-19 Patients Presumed to be Treated wi
England, (2023), p. 2023.2002.20 and Outcomes of COVID-19 Patients Presumed to be Treated with Sotrovimab in NHS Hospitals in
England, (2023), p. 2023.2002.2008.23285654.
N. Peiffer-Smadja, A. Bridier-Nahmias, V.M. Ferré, C. Charpentier, M. Garé, C. Riou

and Outcomes Outcomes Outcomes Outcomes Outcomes Outcomes Outcomes Outcomes Capitan in New York England, (2023), p. 2023.2002.2008.23285654.
N. Peiffer-Smadja, A. Bridier-Nahmias, V.M. Ferré, C. Charpentier, M. Garé, C. Ri England, (2024), p. 2020.
N. Peiffer-Smadja, A. Bridier-Nahmias, V.M. Ferr
Lavallée, J. Ghosn, L. Kramer, D. Descamps, Y. Ya
Mutation Following Bamlanivimab Monotherap
Variant of SARS-CoV-2, *Viruses* 13 (2021). n. Perfer-Smary, A. Bridger, A. Bridger, A. Bridger, C. P. Peirs, P. Peirs, A. Bridger, A. Alleman, A. Alleman
Lavallée, J. Ghosn, L. Kramer, D. Descamps, Y. Yazdanpanah and B. Visseaux, Emergence of E484K
Mutation Followi Mutation Following Bamlanivimab Monotherapy among High-Risk Patients Infected with the Alph
Variant of SARS-CoV-2, *Viruses* 13 (2021)
F. Pommeret, J. Colomba, C. Bigenwald, A. Laparra, S. Bockel, A. Bayle, J.M. Michot, T.

Variant of SARS-CoV-2, *Viruses* 13 (2021).
F. Pommeret, J. Colomba, C. Bigenwald, A. Laparra, S. Bockel, A. Bayle, J.M. Michot, T. Hueso, L. Albiges,
P. Tiberghien, S. Marot, A. Jary, K. Lacombe, F. Barlesi, F. Griscelli in COVID-19 patients with B-cell malignancies, Annals of Oncology (2021). F. Tiberghien, S. Marot, A. Jary, K. Lacombe, F. Barlesi, F. Griscelli and E. Colomba, Bamlanivimab+
etesevimab therapy induces SARS-CoV-2 immune escape mutations and secondary clinical deterioration
in COVID-19 patients w P. The D. B. March, Theory, A. Theory, A. S. Covid H. March, A. Theorem and Secondary clinical deterio
In COVID-19 patients with B-cell malignancies, *Annals of Oncology* (2021).
M. Ragonnet-Cronin, R. Nutalai, J. Huo, A.

in COVID-19 patients with B-cell malignancies, *Annals of Oncology* (2021).
M. Ragonnet-Cronin, R. Nutalai, J. Huo, A. Dijokaite-Guraliuc, R. Das, A. Tuekprakhon, P. Supasa, C. Liu,
M. Selvaraj, N. Groves, H. Hartman, N. E in COVID-19 patients with B-cell malignatieles, Amilas by Oncology (2021).
M. Ragonnet-Cronin, R. Nutalai, J. Huo, A. Dijokaite-Guraliuc, R. Das, A. Tuo
M. Selvaraj, N. Groves, H. Hartman, N. Ellaby, J.M. Sutton, M.W. Baha M. Selvaraj, N. Groves, H. Hartman, N. Ellaby, J.M. Sutton, M.W. Bahar, D. Zhou, E. Fry, J. Ren, C. Brown, P. Klenerman, S.J. Dunachie, J. Mongkolsapaya, S. Hopkins, M. Chand, D.I. Stuart, G.R. Screaton and S. Rokadiya, Ge M. Selvaraj, N. Selvaraj, M. Selvara, M. Selvar, M. Selvara, M. N. Selvara, S. Henerman, S.J. Dunachie, J. Mongkolsapaya, S. Hopkins, M. Chand, D.I. Stuart, G.R. Screaton and S.
Rokadiya, Genome-first detection of emerging P. Klenerman, S.R. S. Martins, P. Klener, J., P. Kleptins, Antennan, S.A. Stuart, S.A. Stuart, M. S.
R.J. Rockett, K. Basile, S. Maddocks, W. Fong, J.E. Agius, J. Johnson-Mackinnon, A. Arnott, S. Chandra, N.
Gall, J.L. Dra

bioRxiv (2022), p. 2022.2007.2014.500063.
R.J. Rockett, K. Basile, S. Maddocks, W. Fong, J.E. Agius, J. Johnson-Mackinnon, A. Arnott, S. Chandra, N
Gall, J.L. Draper, E. Martinez, E.M. Sim, C. Lee, C. Ngo, M. Ramsperger, A bionaly (2022), p. 2022.2007.2014.500005.
R.J. Rockett, K. Basile, S. Maddocks, W. Fon_i
Gall, J.L. Draper, E. Martinez, E.M. Sim, C. Le
Ko, L. Lim, N. Gilroy, M.V. Sullivan, S.C.-A. Cl
mutations in SARS-CoV-2 Delta varia R.J. Rockett, K. Basile, S. Maddocks, W. Fong, J.E. Agius, J. Johnson-Mackinnon, A. Arnott, S. Chandra, M. Fan, Hartanetteper, Erman Marty, Elmin May, Pressy, Prings, And Martyperger, A.M. Pan, C. Drang, M. Pennell, D
Ko, L. Lim, N. Gilroy, M.V. Sullivan, S.C.-A. Chen, J. Kok, D.E. Dwyer and V.L. Sintchenko, Resistance
mutation Matations in SARS-CoV-2 Delta variant after sotrovimab use, N Engl J Med 386 (2021), pp. 1477-14
D.-K. Ryu, H.-M. Woo, B. Kang, H. Noh, J.-I. Kim, J.-M. Seo, C. Kim, M. Kim, J.-W. Kim, N. Kim, P. Jeon
Lee, J.-S. Yang, K.-C mutations in SARS-Cov-2 Delta variant after sotroviniab use, *N Engl 3 Med 386* (2021), pp. 1477-1475.
D.-K. Ryu, H.-M. Woo, B. Kang, H. Noh, J.-I. Kim, J.-M. Seo, C. Kim, M. Kim, J.-W. Kim, N. Kim, P. Jeon, H
Lee, J.-S. Y Lee, J.-S. Yang, K.-C. Kim, J.-Y. Lee, M.-H. Lee, S.-S. Oh, H.-Y. Chung, K.-S. Kwon and S.-Y. Lee, The in vitro
and in vivo potency of CT-P59 against Delta and its associated variants of SARS-CoV-2, (2021), p.
2021.2007.20 and in vivo potency of CT-P59 against Delta and its associated variants of SARS-CoV-2, (2021), p.
2021.2007.2023.453472.
A.P. Sabin, C.S. Richmond and P.A. Kenny, Emergence and onward transmission of a SARS-CoV-2 E484K
var

and 2021.2007.2023.453472.
A.P. Sabin, C.S. Richmond and P.A. Kenny, Emergence and onward transmission of a SARS-CoV-2 I
variant among household contacts of a bamlanivimab-treated patient., *Diagn Microbiol Infect Dis*
(20 A.P. Sabin, C.S. Richmond
variant among household
(2022), p. 115656.
E.M. Scherer, A. Babiker, A.P. Sabin, C.S. Richmond and P.A. Sabin, C.S. Richmond and P.A. P. Sabin, Diagn Microbiol Infect Dis 103
(2022), p. 115656.
E.M. Scherer, A. Babiker, M.W. Adelman, B. Allman, A. Key, J.M. Kleinhenz, R.M. Langsjoen, P.-V.

variant among household contacts or a bamlanivimab-treated patient., *Didyn Microbiol Infect Dis* 103
(2022), p. 115656.
E.M. Scherer, A. Babiker, M.W. Adelman, B. Allman, A. Key, J.M. Kleinhenz, R.M. Langsjoen, P.-V. Nguy .
E.M. Scherer, A. Ba
I. Onyechi, J.D. She
Weissman, Y. Xu, J.
Evolution and Imm I. Onyechi, J.D. Sherman, T.W. Simon, H. Soloff, J. Tarabay, J. Varkey, A.S. Webster, D. Weiskopf, D.B.
Weissman, Y. Xu, J.J. Waggoner, K. Koelle, N. Rouphael, S.M. Pouch and A. Piantadosi, SARS-CoV-2
Evolution and Immune Weissman, Y. Xu, J.J. Waggoner, K. Koelle, N. Rouphael, S.M. Pouch and A. Piantadosi, SARS-CoV-2
Evolution and Immune Escape in Immunocompromised Patients, 386 (2022), pp. 2436-2438.
L.M. Simons, E.A. Ozer, S. Gambut, T.J.

Weissman, Y. Xu, J.J. Waggoner, K. Koelle, N. Rouphael, S.M. Pouch and A. Piantadosi, SARS-CoV-2 Evolution and Immune Escape in Immunocompromised Fatients, 386 (2022), pp. 2436-2438.
L.M. Simons, E.A. Ozer, S. Gambut, T.J. Dean, L. Zhang, P. Bhimalli, J.R. Schneider, J.I. Mamede
R. Karmali, L.I. Gordon, R. Lorenzo-Red R. Karmali, L.I. Gordon, R. Lorenzo-Redondo and J.F. Hultquist, De novo emergence of SARS-CoV-2 spike
mutations in immunosuppressed patients, *Transplant infectious disease : an official journal of the*
Transplantation So mutations in immunosuppressed patients, *Transplant infectious disease : an official journal of the*
Transplantation Society 24 (2022), p. e13914.
E. Stadler, M.T. Burgess, T.E. Schlub, K.L. Chai, Z.K. McQuilten, E.M. Wo

mutations in immunosuppressed patients, Transplant infectious disease : an official formula of the
Transplantation Society 24 (2022), p. e13914.
E. Stadler, M.T. Burgess, T.E. Schlub, K.L. Chai, Z.K. McQuilten, E.M. Wood, Transplantation Society 24 (2022), p. e13314.
E. Stadler, M.T. Burgess, T.E. Schlub, K.L. Chai,
Cromer, M.P. Davenport and D.S. Khoury, Mor
(2022a), p. 2022.2011.2022.22282199.
E. Stadler, K.L. Chai, T.E. Schlub, D. Cromer E. Stadler, M.P. Bavenport and D.S. Khoury, Monoclonal antibody levels and protection from COVID-19,
(2022a), p. 2022.2011.2022.22282199.
E. Stadler, K.L. Chai, T.E. Schlub, D. Cromer, M.N. Polizzotto, S.J. Kent, C. Beeche

(2022a), p. 2022.2011.2022.22282199.
E. Stadler, K.L. Chai, T.E. Schlub, D. Cromer, M.N. Polizzotto, S.J. Kent, C. Beecher, H. White, T. Turner,
Skoetz, L. Estcourt, Z.K. McQuilten, E.M. Wood, D.S. Khoury and M.P. Davenpor .
E. Stadler, K.L. Chai, T.E. Schlub, D. Cron
Skoetz, L. Estcourt, Z.K. McQuilten, E.M
passive antibody efficacy in SARS-CoV-2
T.N. Starr, A.J. Greaney, A. Addetia, W.\ Skoetz, L. Estcourt, Z.K. McQuilten, E.M. Wood, D.S. Khoury and M.P. Davenport, Determinants of
passive antibody efficacy in SARS-CoV-2 infection, (2022b), p. 2022.2003.2021.22272672.
T.N. Starr, A.J. Greaney, A. Addetia,

Show in the Littlen, Littlen, Littlen, 2002, 2003, 2022, 2003, 2021.222222222222.
Passive antibody efficacy in SARS-CoV-2 infection, (2022b), p. 2022.2003.2021.22272672.
T.N. Starr, A.J. Greaney, A. Addetia, W.W. Hannon, M passive antibody entropy in the set of the same of process in SARS-Cover-2 in Section, A.S. Dingens, J.Z. Li an
Prospective mapping of viral mutations that escape antibodies used to treat COVID-19, Sci
p. eabf9302. Prospective mapping of viral mutations that escape antibodies used to treat COVID-19, Science (2021), p. eabf9302. Prospective mapping of viral mutations that escape antibodies used to treat COVID-19, Science (2021),
p. eabf9302.
18 p. eabf9302.

The Ham, Emma N.R. Landau, Convalescent-Phase Sera and Vaccine-Elicited Antibodies Largely Maintai
Neutralizing Titer against Global SARS-CoV-2 Variant Spikes, *mBio* 12 (2021a), p. e0069621.
T. Tada, H. Zhou, B.M. Dcosta,

Mulligan and Nikala and N.R. Landau, Neutralizing Titer against Global SARS-CoV-2 Variant Spikes, *mBio* 12 (2021a), p. e0069621.
T. Tada, H. Zhou, B.M. Dcosta, M.I. Samanovic, V. Chivukula, R. Herati, S.R. Hubbard, M.J. M Neutralizing Titer against Global SARS-CoV-2 Variant Spikes, *mbio* 12 (2021a), p. e0009021.
T. Tada, H. Zhou, B.M. Dcosta, M.I. Samanovic, V. Chivukula, R. Herati, S.R. Hubbard, M.J. M
N.R. Landau, Increased resistance of N.R. Landau, Increased resistance of SARS-CoV-2 Omicron Variant to Neutralization by Vaccine-Elicited
and Therapeutic Antibodies, *EBioMedicine* (2022a), p. 2021.2012.2028.474369.
T. Tada, H. Zhou, B.M. Dcosta, M.I. Samano

N.R. Landau, M.R. Landau, Increased and Therapeutic Antibodies, *EBioMedicine* (2022a), p. 2021.2012.2028.474369.
T. Tada, H. Zhou, B.M. Dcosta, M.I. Samanovic, M.J. Mulligan and N.R. Landau, Partial resistance of SAR!
CoV

and Therapeutic Antibodies, *EbioMedicine* (2022a), p. 2021.2012.2028.474369.
T. Tada, H. Zhou, B.M. Dcosta, M.I. Samanovic, M.J. Mulligan and N.R. Landau, P
CoV-2 Delta variants to vaccine-elicited antibodies and convales Frontiers in immunology 13 (2022b), p. 797589. CoV-2 Delta variants to vaccine-elicited antibodies and convalescent sera, *iScience* (2021b).
T. Tada, H. Zhou, M.I. Samanovic, B.M. Dcosta, A. Cornelius, R.S. Herati, M.J. Mulligan and N.R. Landau,
Neutralization of SARS

Piccoli, D.J. Pascall, J. Dillen, S. Lytras, N. Czudnochowski, R. Shah, M. Meury, N. Jesudason, A. De Marco, Neutralization of Neutralian of Santa Coventinal Vector Vaccine-Elicited Antibodies,
Frontiers in immunology 13 (2022b), p. 797589.
Piccoli, D.J. Pascall, J. Dillen, S. Lytras, N. Czudnochowski, R. Shah, M. Meury, N. Jesud F.C. Thomson, L.E. Rosen, J.G. Shepherd, R. Spre
Piccoli, D.J. Pascall, J. Dillen, S. Lytras, N. Czudno
K. Li, J. Bassi, A. O'Toole, D. Pinto, R.M. Colquho
V.B. Sreenu, J. Nix, R.F. Jarrett, M. Beltramello, I K. Li, J. Bassi, A. O'Toole, D. Pinto, R.M. Colquhoun, K. Culap, B. Jackson, F. Zatta, A. Rambaut, S. Jaconi,
V.B. Sreenu, J. Nix, R.F. Jarrett, M. Beltramello, K. Nomikou, M. Pizzuto, L. Tong, E. Cameroni, N. Johnson,
A. K. Li, J. Bassi, A. O'Toole, D. Pinto, R.M. Colquhoun, K. Culap, B. Jackson, F. Zatta, A. Rambaut, S. Jaconi,
V.B. Sreenu, J. Nix, R.F. Jarrett, M. Beltramello, K. Nomikou, M. Pizzuto, L. Tong, E. Cameroni, N. Johnson
A. W V.B. Sreenu, J. Nix, R.F. Jarrett, M. Beltramello, K. Nomikou, M. Pizzuto, L. Tong, E. Cameroni, N. Johnso
A. Wickenhagen, A. Ceschi, D. Mair, P. Ferrari, K. Smollett, F. Sallusto, S. Carmichael, C. Garzoni, J.
Nichols, M. V.B. Wickenhagen, A. Ceschi, D. Mair, P. Ferrari, K. Smollett, F. Sallusto, S. Carmichael, C. Garzoni, J.
Nichols, M. Galli, J. Hughes, A. Riva, A. Ho, M.G. Semple, P.J.M. Openshaw, J.K. Baillie, S.J. Rihn, S.J.
Lycett, H. A. Wichols, M. Galli, J. Hughes, A. Riva, A. Ho, M.G. Semple, P.J.M. Openshaw, J.K. Baillie, S.J. Rihn, S.J. Lycett, H.W. Virgin, A. Telenti, D. Corti, D.L. Robertson and G. Snell, The circulating SARS-CoV-2 spine variant Nichols, M. Galli, M. Galli, D. Gorti, D. L. Robertson and G. Snell, The circulating SARS-CoV-2 spik
Variant N439K maintains fitness while evading antibody-mediated immunity, (2020), p.
2020.2011.2004.355842.
A. Truffot, J variant N439K maintains fitness while evading antibody-mediated immunity, (2020), p.
2020.2011.2004.355842.
A. Truffot, J. Andreani, M. Le Marechal, A. Caporossi, O. Epaulard, P. Poignard and L. Sylvie, SARS-CoV
Variants i

variant 2020.2011.2004.355842.
A. Truffot, J. Andreani, M. Le Marechal, A. Caporossi, O. Epaulard, P. Poignard and L. Sylv
Variants in Immunocompromised Patient Given Antibody Monotherapy, *Emerging infect*
(2021). 2020.2011.2004.355842. Variants in Immunocompromised Patient Given Antibody Monotherapy, *Emerging infectious diseases* 27 (2021).
(2021).
P.L. Tzou, K. Tao, J. Nouhin, S.-Y. Rhee, B.D. Hu, S. Pai, N. Parkin and R.W. Shafer, Coronavirus Antivira

Research Database (CoV-RDB): An Online Database Designed to Facilitate Comparisons between
Candidate Anti-Coronavirus Compounds, 12 (2020), p. 1006. (2022).
P.L. Tzo
Researc
Candida P.L. Tzou, K. Tao, J. Nouhin, S.-Y. Rhee, B.D. Hu, S. Pai, N. Parkin and R.W. Shafer, Coronavirus Antiviral

Candidate Anti-Coronavirus Compounds, 12 (2020), p. 1006.
C. Vellas, A. Del Bello, D. Alexa, Z. Steinmeyer, L. Tribaudeau, N. Ranger, N. Jeanne, G. Martin-Blo
Delobel, N. Kamar and J. Izopet, Influence of neutralizing mono Candidate Anti-Coronavirus Compounds, 12 (2020), p. 1006.
C. Vellas, A. Del Bello, D. Alexa, Z. Steinmeyer, L. Tribaudeau,
Delobel, N. Kamar and J. Izopet, Influence of neutralizing mor
quasispecies in patients with COVID-Delobel, N. Kamar and J. Izopet, Influence of neutralizing monoclonal antibodies on the SARS-CoV-2 quasispecies in patients with COVID-19, *Clin Microb Infect* (2021).
C. Vellas, N. Kamar and J. Izopet, Resistance mutation

Delongion in the line product of the Microb Infect (2021).
Quasispecies in patients with COVID-19, *Clin Microb Infect* (2021).
C. Vellas, N. Kamar and J. Izopet, Resistance mutations in SARS-CoV-2 Omicron variant after
ti tixagevimab-cilgavimab treatment, Journal of Infection 85 (2022a), pp. e162-e163.

tixagevimab-cilgavimab treatment, *Journal of Infection* 85 (2022a), pp. e162-e163.
C. Vellas, P. Trémeaux, A. Del Bello, J. Latour, N. Jeanne, N. Ranger, C. Danet, G. Martin-Blon
Delobel, N. Kamar and J. Izopet, Resistanc tixagevimab-cilgavimab treatment, Journal by Injection 83 (2022a), pp. e102-e103.
C. Vellas, P. Trémeaux, A. Del Bello, J. Latour, N. Jeanne, N. Ranger, C. Danet, G. Ma
Delobel, N. Kamar and J. Izopet, Resistance mutations Delobel, N. Kamar and J. Izopet, Resistance mutations in SARS-CoV-2 Omicron variant in patients treated with sotrovimab, *Clinical Microbiology and Infection* 28 (2022b), pp. 1297-1299.
L. Wang, T. Zhou, Y. Zhang, E.S. Yan

Delong, Martin Microllipper, Merchine Microlom 28 (2022b), pp. 1297-1299.
L. Wang, T. Zhou, Y. Zhang, E.S. Yang, C.A. Schramm, W. Shi, A. Pegu, O.K. Oloniniyi, A.R. Henry, S. Darko,
S.R. Narpala, C. Hatcher, D.R. Martinez, with sotrovimab, e*llinen Microbiology and Injection 28* (2022b), pp. 1297-1299.
L. Wang, T. Zhou, Y. Zhang, E.S. Yang, C.A. Schramm, W. Shi, A. Pegu, O.K. Olonin
S.R. Narpala, C. Hatcher, D.R. Martinez, Y. Tsybovsky, E. P S.R. Narpala, C. Hatcher, D.R. Martinez, Y. Tsybovsky, E. Phung, O.M. Abiona, A. Antia, E.M. Cale, L.A.
Chang, M. Choe, K.S. Corbett, R.L. Davis, A.T. DiPiazza, I.J. Gordon, S.H. Hait, T. Hermanus, P. Kgagudi, F.
Laboune, Chang, M. Choe, K.S. Corbett, R.L. Davis, A.T. DiPiazza, I.J. Gordon, S.H. Hait, T. Hermanus, P. Kgagudi,
Laboune, K. Leung, T. Liu, R.D. Mason, A.F. Nazzari, L. Novik, S. O'Connell, S. O'Dell, A.S. Olia, S.D.
Schmidt, T. Laboune, K. Leung, T. Liu, R.D. Mason, A.F. Nazzari, L. Novik, S. O'Connell, S. O'Dell, A.S. Olia, S.D.
Schmidt, T. Stephens, C.D. Stringham, C.A. Talana, I.-T. Teng, D.A. Wagner, A.T. Widge, B. Zhang, M.
Roederer, J.E. Le Laboune, K. Leung, T. Liu, R.D. Mason, A.F. Nazzari, L. Novik, S. O'Connell, S. O'Dell, A.S. Olia, S.D.
Schmidt, T. Stephens, C.D. Stringham, C.A. Talana, I.-T. Teng, D.A. Wagner, A.T. Widge, B. Zhang, M.
Roederer, J.E. Le Schmidt, T. Stephens, T. Stephen
Schmidt, P. St. Stephens, C. D. Stephens, C.A. C.A. Talana, I.P. C.A. Doria-Rose, R.S. Baric, I.
Graham, A.B. M Graham, A.B. McDermott, D.C. Douek, P.D. Kwong, J.R. Mascola, N.J. Sullivan and J. Misasi, Ultrapotent antibodies against diverse and highly transmissible SARS-CoV-2 variants, 373 (2021a), p. eabh1766.
P. Wang, M.S. Nair, antibodies against diverse and highly transmissible SARS-CoV-2 variants, **373** (2021a), p. eabh1766.
P. Wang, M.S. Nair, L. Lihong, S. Iketani, Y. Luo, Y. Guo, M. Wang, J. Yu, B. Zhang, P.D. Kwong, B.S.
Graham, J.R. Masco antibodies against diverse and highly transmissible SARS-CoV-2 variants, 373 (2021a), p. eabh1766.
P. Wang, M.S. Nair, L. Lihong, S. Iketani, Y. Luo, Y. Guo, M. Wang, J. Yu, B. Zhang, P.D. Kwong, B.S.
Graham, J.R. Mascola, P. P. Wang, M. P. P. Mascola, J.Y. Chang, M.T. Yin, M.E. Sobieszczyk, C.A. Kyratsous, L. Shapiro, Z. Sheng, Y.
Huang and D.D. Ho, Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7, Nature 593 (pp. 130-135. Graham, J.R. Mascola, J.R. Chang, M.R. May M.R. Collection, J.R. May Records, D.R. Andres 593 (20
Huang and D.D. Ho, Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7, Nature 593 (20)
pp. 130-135. Huang and D.D. Ho, Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7, Nature 593 (2021b),
pp. 130-135. pp.
130-135.
130-135.

R. Hang, H. Lie, Y. Mann, S. Li, M. M. Man, M. Hang, L. Liu and D. Ho, Antibody evasion by SARS-CoV-2 Omicron subvariants BA.2.12.1, BA.4 and BA.5, *Nature* 608 (2022a), pp. 603–608.
Q. Wang, S. Iketani, Z. Li, Y. Guo, A.Y

R. Wang, Q. Zhang, J. Ge, W. Ren, R. Zhang, J. Lan, B. Ju, B. Su, F. Yu, P. Chen, H. Liao, Y. Feng, X. Li, X. S Covez Omicron subvariants BA.2.12.1, BA.4 and BA.5, Nature 608 (2022a), pp. 603–608.
Q. Wang, S. Iketani, Z. Li, Y. Guo, A.Y. Yeh, M. Liu, J. Yu, Z. Sheng, Y. Huang, L. Liu and D.D
characterization of the SARS-CoV-2 Omicro Characterization of the SARS-CoV-2 Omicron subvariant BA.2.75, (2022b), p. 2022.2007.2031.502235.
R. Wang, Q. Zhang, J. Ge, W. Ren, R. Zhang, J. Lan, B. Ju, B. Su, F. Yu, P. Chen, H. Liao, Y. Feng, X. Li, X. Sh
Z. Zhang, F characterization of the SaRs-Cov-2 Omicron of the SARS-Cov-2 Omicropheration of the SARS-Cov-2 Variant mutations
2. Zhang, F. Zhang, Q. Ding, T. Zhang, X. Wang and L. Zhang, Analysis of SARS-CoV-2 variant mutations
reveals R. P. M., S. Zhang, D. P. J. P. Wang, W. Land, P. P. Lan, P. P. Lan, W. P. Lan, W. P. Lan, W. P. B., W. 21, W.
2. Zhang, F. Zhang, Q. Ding, T. Zhang, X. Wang and L. Zhang, Analysis of SARS-CoV-2 variant mutations
reveals n zhanng, F. Zhang, Q. Dang, F. Zhang, M. Phang, M. Ding, Thang, Phang Persenting Termin Hermin Mented
Immunity 54 (2021c), pp. 1611-1621.e1615.
Y. Wang, X. Zhang, J. Liu, Y. Wang, W. Zhan, M. Liu, M. Zhang, Q. Wang, Q. Liu,

*Immunity 5*4 (2021c), pp. 1611-1621.e1615.
Y. Wang, X. Zhang, J. Liu, Y. Wang, W. Zhan, M. Liu, M. Zhang, Q. Wang, Q. Liu, T. Zhu, Y. Wen, Z. Chen, J.
Zhao, F. Wu, L. Sun and J. Huang, Combating the SARS-CoV-2 Omicron var neutralizing antibodies, (2022c), p. 2022.2001.2030.478305.
Z. Wang, F. Schmidt, Y. Weisblum, F. Muecksch, C.O. Barnes, S. Finkin, D. Schaefer-Babajew, M. Cipolla, C. Y. Wang, W. Zhang, W. Peng, W. Peng, W. Zhan, W. Zhang, Q. Peng, Q. Peng, W. 2hp, W. 2hp, Z. 2hp, 2.
Zhao, F. Wu, L. Sun and J. Huang, Combating the SARS-CoV-2 Omicron variant with non-Omicron
neutralizing antibodies, (202

2002)
The Same Controlling antibodies, (2022c), p. 2022.2001.2030.478305.
Z. Wang, F. Schmidt, Y. Weisblum, F. Muecksch, C.O. Barnes, S. Finkin, D. Schaefer-Babajew, M. C
Gaebler, J.A. Lieberman, Z. Yang, M.E. Abernathy, K neutralizing antibodies, (2022c), p. 2022.2001.2030.478305. Gaebler, J.A. Lieberman, Z. Yang, M.E. Abernathy, K.E. Huey-Tubman, A. Hurley, M. Turroja, K.A. West, K.
Gordon, K.G. Millard, V. Ramos, J.D. Silva, J. Xu, R.A. Colbert, R. Patel, J.P. Dizon, C. Unson-O'Brien, I.
Shimeliov Gordon, K.G. Millard, V. Ramos, J.D. Silva, J. Xu, R.A. Colbert, R. Patel, J.P. Dizon, C. Unson-O'Brien, I.
Shimeliovich, A. Gazumyan, M. Caskey, P.J. Bjorkman, R. Casellas, T. Hatziioannou, P.D. Bieniasz and M.C.
Nussenzw Shimeliovich, A. Gazumyan, A. Gazumyan, A. Gazuman, A. Gazuman, A. Gazuman, A. Gazuman, BioRxiv [Preprint]
(2021d), p. 2021.2001.2015.426911.
K. Westendorf, S. Žentelis, D. Foster, P. Vaillancourt, M. Wiggin, E. Lovett, J.

Nussenzweig, mRNA vaccine-encited antibodies to SARS-CoV-2 and circulating variants. bioRxiv [Preprint]
(2021d), p. 2021.2001.2015.426911.
K. Westendorf, S. Žentelis, D. Foster, P. Vaillancourt, M. Wiggin, E. Lovett, J. He ,
K. Westendorf, S. Žentelis, D. Foster,
Sauder, L. Kraft, Y. Hwang, R.W. Siege
M.A. Smith, D.W. Collins, D. Pellacani
A. O'Neill, C. Cohen, J. Dye, K.I. Huie, Sauder, L. Kraft, Y. Hwang, R.W. Siegel, J. Chen, B.A. Heinz, R.E. Higgs, N. Kalleward, K. Jepson, R. Goya
M.A. Smith, D.W. Collins, D. Pellacani, P. Xiang, V. de Puyraimond, M. Ricicova, L. Devorkin, C. Pritchai
A. O'Neil Samery, Littlery, Littlery, Microsofy, P. 2012, J. Microsofy, Microsofy, Microsofy, M. A. Smith, D.W. Collins, D. Pellacani, P. Xiang, V. de Puyraimond, M. Ricicova, L. Devorkin, C. Pritchard
A. O'Neill, C. Cohen, J. Dye, M. O'Neill, C. Cohen, J. Dye, K.I. Huie, C.V. Badger, D. Kobasa, J. Audet, J.J. Freitas, S. Hassanali, I. Hughes,
L. Munoz, H.C. Palma, B. Ramamurthy, R.W. Cross, T.W. Geisbert, I. Lanz, L. Anderson, P. Sipahimalani,
K.S. L. S. Corbett, L. Wang, E.S. Yang, Y. Zhang, W. Shi, B.S. Graham, J.R. Mascola, T.L. Fernandez, C.L. Hanse
E. Falconer, B.E. Jones and B.C. Barnhart, LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2
variants, *Cel* K. Corpett, L. Marcon, L. Marcon, M. Marcon, L. P. Corpett, L. Marcon, M. M. Marcon, M. M. M. M. S. Corpett, L.
K. Falconer, B.E. Jones and B.C. Barnhart, LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2
M.Y. Wu,

variants, *Cell Rep* (2022), p. 2021.2004.2030.442182.
M.Y. Wu, E.J. Carr, R. Harvey, H.V. Mears, S. Kjaer, H. Townsley, A. Hobbs, M. Ragno, L.S. Herman, L.
Adams, S. Gamblin, M. Howell, R. Beale, M. Brown, B. Williams, S. variants, Cell Rep (2022), p. 2021.2004.2030.442182.
M.Y. Wu, E.J. Carr, R. Harvey, H.V. Mears, S. Kjaer, H.
Adams, S. Gamblin, M. Howell, R. Beale, M. Brown, B.
D.L.V. Bauer, WHO's Therapeutics and COVID-19 Livin
Lancet Adams, S. Gamblin, M. Howell, R. Beale, M. Brown, B. Williams, S. Gandhi, C. Swanton, E.C. Wall and
D.L.V. Bauer, WHO's Therapeutics and COVID-19 Living Guideline on mAbs needs to be reassessed,
Lancet 400 (2022), pp. 21

Adams, S. Gauer, WHO's Therapeutics and COVID-19 Living Guideline on mAbs needs to be reassessed,
Lancet 400 (2022), pp. 2193-2196.
W. Yao, D. Ma, H. Wang, X. Tang, C. Du, H. Pan, C. Li, H. Lin, M. Farzan, J. Zhao, Y. Li a 2012 200 (2022), pp. 2133-2136.
W. Yao, D. Ma, H. Wang, X. Tang, C
of SARS-CoV-2 spike mutations on :
2021.2001.2027.428353.
C. Yi, X. Sun, Y. Lin, C. Gu, L. Ding, X of SARS-CoV-2 spike mutations on animal ACE2 usage and in vitro neutralization sensitivity, (2021), p.
2021.2001.2027.428353.
C. Yi, X. Sun, Y. Lin, C. Gu, L. Ding, X. Lu, Z. Yang, Y. Zhang, L. Ma, W. Gu, A. Qu, X. Zhou, X

of Sars-Coventianus 2021, 2001, 2021, 2021, 2021, 2021, 2021, 2021, 2021, 2021, 2021, 2021, 2021, 2021, 2021, 2
C. Yi, X. Sun, Y. Lin, C. Gu, L. Ding, X. Lu, Z. Yang, Y. Zhang, L. Ma, W. Gu, A. Qu, X. Zhou, X. Li, J. Xu, Z 2021.2001.2027.428353. Y. Xie, H. Lu and B. Sun, Comprehensive mapping of binding hot spots of SARS-CoV-2 RBD-specific
neutralizing antibodies for tracking immune escape variants, *Genome Medicine* 13 (2021), p. 164.
H. Yi, 2019 Novel Coronaviru neutralizing antibodies for tracking immune escape variants, *Genome Medicine* 13 (2021), p. 164.
H. Yi, 2019 Novel Coronavirus Is Undergoing Active Recombination, *Clinical Infectious Diseases* 71
pp. 884-887.
M. Yuan, D. neutralizing antibodies for tracking immune escape variants, oc*home Wedielle 13 (2021), p. 104.*
H. Yi, 2019 Novel Coronavirus Is Undergoing Active Recombination, *Clinical Infectious Diseases* **71**
pp. 884-887.
D.R. Burt

H. H. 2019 Novel Coronavirus Is Undergoing Active Recombination, *emilea injectious Diseases 7*1 (2020),
pp. 884-887.
M. Yuan, D. Huang, C.-C.D. Lee, N.C. Wu, A.M. Jackson, X. Zhu, H. Liu, L. Peng, M.J. van Gils, R.W. Sand pp. 334
M. Yuan, D. F
D.R. Burton, S
functional rai
2021.2002.20 M. Yuan, D. Huang, C.-C.D. Lee, N.C. Wu, A.M. Jackson, X. Zhu, H. Liu, L. Peng, M.J. van Gils, R.W. Sanders, functional ramifications of antigenic drift in recent SARS-CoV-2 variants, (2021), p.
2021.2002.2016.430500.
H. Zhou, B.M. Dcosta, N.R. Landau and T. Tada, Resistance of SARS-CoV-2 Omicron BA.1 and BA.2
Variants to Vaccin

functional 2002.2016.430500.
The Zhou, B.M. Dcosta, N.R. Landau and T. Tada, Resistance of SARS-CoV-2 Omicron
T. Zhou, L. Wang, J. Misasi, A. Pegu, Y. Zhang, D.R. Harris, A.S. Olia, C.A. Talana, E.S.
T. Zhou, L. Wang, J. M H. Zhou, B.M. Dcosta, N.R
Variants to Vaccine-Elicite
T. Zhou, L. Wang, J. Misas
Choe, W. Shi, I.-T. Teng, A Mariants to Vaccine-Elicited Sera and Therapeutic Monoclonal Antibodies, *Viruses* 14 (2022).
T. Zhou, L. Wang, J. Misasi, A. Pegu, Y. Zhang, D.R. Harris, A.S. Olia, C.A. Talana, E.S. Yang, M. Chen
Choe, W. Shi, I.-T. Teng Variants to Vaccine-Elicited Sera and Therapeutic Monoclonal Antibodies, Viruses 14 (2022).
T. Zhou, L. Wang, J. Misasi, A. Pegu, Y. Zhang, D.R. Harris, A.S. Olia, C.A. Talana, E.S. Yang, M.
Choe, W. Shi, I.-T. Teng, A. Cr Choe, W. Shi, I.-T. Teng, A. Creanga, C. Jenkins, K. Leung, T. Liu, E.-S.D. Stancofski, T. Stephens, B. Zhang,
Y. Tsybovsky, B.S. Graham, J.R. Mascola, N.J. Sullivan and P.D. Kwong, Structural basis for potent Y. Tsybovsky, B.S. Graham, J.R. Mascola, N.J. Sullivan and P.D. Kwong, Structural basis for potent
antibody neutralization of SARS-CoV-2 variants including B.1.1.529, (2021), p. 2021.2012.2027.474307.
20 antibody neutralization of SARS-CoV-2 variants including B.1.1.529, (2021), p. 2021.2012.2027.4
20 and $\frac{3}{20}$ variants including B.1.1.529, (2021), p. 2021.

0.75 bebtelovimab authorized (Feb 2022) Proportion of all samples
 $\frac{6}{9}$ 0.25 bamlanivimab cilgavimab authorized +etesevimab authorized (Dec 2021) (Nov 2020) $0.00 \cdot$ 2022 2020 2021 2023

S:346

S:444

Sequences over time in World

https://covspectrum.org/explore/World/AllSa mples/AllTimes/variants?variantQu ery=S%3A346&variantQuery1=S%3 A493&variantQuery2=S%3A444&an alysisMode=CompareEquals&

Plot by cov-spectrum.org, enabled by data from GISAID

S:493